ASpdb: an integrative knowledgebase of human protein isoforms from experimental and AI-predicted structures

Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene Expressed Sample Information
	Fusion Gene and Drug/Small Molecule Search from PubMed Abstracts
	Fusion Gene and Diseases from the Found PubMed Abstracts
	Fusion Gene and Diseases from Manual Curation and Other Resource
	Details of the Found Drugs/Small Molecules
	Clinical Trials of the Found Drugs/Small Molecules
	Fusion-Positive Patients' Treatment Records
	Generative AI Summary Sentence of the Relationship Between Fusion Gene and Small Molecule that Have at Least Thrree PMIDs from PubMed.

EML4::ALK

Fusion Gene Summary

Fusion Gene Summary

Fusion gene name: EML4-ALK
	Hgene	Tgene
Gene symbol	EML4	ALK
Gene ID	27436	238
Gene name	EMAP like 4	ALK receptor tyrosine kinase
Synonyms	C2orf2\|ELP120\|EMAP-4\|EMAPL4\|ROPP120\|EML4	ALK1\|CD246\|NBLST3\|ALK
Cytomap	2p21	2p23.2-p23.1
Type of gene	protein-coding	protein-coding
Description	echinoderm microtubule-associated protein-like 4echinoderm microtubule associated protein like 4restrictedly overexpressed proliferation-associated proteinropp 120	ALK tyrosine kinase receptorCD246 antigenanaplastic lymphoma receptor tyrosine kinasemutant anaplastic lymphoma kinase
Modification date	20240411	20240411
UniProtAcc	.	.

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	ALK	GO:0007169	cell surface receptor protein tyrosine kinase signaling pathway	25605972\|30061385\|34646012
Tgene	ALK	GO:0016310	phosphorylation	9174053
Tgene	ALK	GO:0038083	peptidyl-tyrosine autophosphorylation	30061385\|34646012
Tgene	ALK	GO:0046777	protein autophosphorylation	9174053
Tgene	ALK	GO:0046777	protein autophosphorylation	9174053

Fusion Gene Expressed Sample Information

Fusion gene information from FusionGDB2.0 (ChiTars 5.0 and ChimerDB 4.0), COSMIC, and CCLE.

* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Sample	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp
ChimerDB4	AB274722	EML4	chr2	42522660	ALK	chr2	29415644
ChimerDB4	TCGA-2Z-A9JJ-01A	EML4	chr2	42472827	ALK	chr2	29446394
ChimerDB4	TCGA-50-8460-01A	EML4	chr2	42492090	ALK	chr2	29446393
ChimerDB4	TCGA-50-8460-01A	EML4	chr2	42492091	ALK	chr2	29446394
ChimerDB4	TCGA-67-6215-01A	EML4	chr2	42491871	ALK	chr2	29446394
ChimerDB4	TCGA-67-6216-01A	EML4	chr2	42491870	ALK	chr2	29446393
ChimerDB4	TCGA-78-7163-01A	EML4	chr2	42522655	ALK	chr2	29446393
ChimerDB4	TCGA-78-7163-01A	EML4	chr2	42522656	ALK	chr2	29446394
ChimerDB4	TCGA-86-A4P8-01A	EML4	chr2	42552694	ALK	chr2	29446394
ChimerDB4	TCGA-E8-A432-01A	EML4	chr2	42491871	ALK	chr2	29449940
ChimerDB4	TCGA-E8-A432-01A	EML4	chr2	42491871	ALK	chr2	29450538
ChimerDB4	TCGA-E8-A432-01A	EML4	chr2	42492091	ALK	chr2	29449940
ChimerDB4	TCGA-E8-A432-01A	EML4	chr2	42492091	ALK	chr2	29450538
ChiTaRS5.0	AB274722	EML4	chr2	42522660	ALK	chr2	29446396
ChiTaRS5.0	AB275889	EML4	chr2	42552694	ALK	chr2	29446394
ChiTaRS5.0	AB374361	EML4	chr2	42491871	ALK	chr2	29446396
ChiTaRS5.0	AB374362	EML4	chr2	42492091	ALK	chr2	29446396
ChiTaRS5.0	AB374364	EML4	chr2	42472827	ALK	chr2	29446396
ChiTaRS5.0	AB374365	EML4	chr2	42472829	ALK	chr2	29446515
ChiTaRS5.0	AB462411	EML4	chr2	42522657	ALK	chr2	29446465
ChiTaRS5.0	AB462412	EML4	chr2	42528532	ALK	chr2	29446382
ChiTaRS5.0	GU797894	EML4	chr2	42531692	ALK	chr2	29446427
ChiTaRS5.0	GU797895	EML4	chr2	42532902	ALK	chr2	29446432
ChiTaRS5.0	JQ828841	EML4	chr2	42483770	ALK	chr2	29446449
COSMIC	1081879	EML4	chr2	42522656	ALK	chr2	29446691
COSMIC	1081880	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1081881	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1107461	EML4	chr2	42525231	ALK	chr2	29446597
COSMIC	1107462	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1146764	EML4	chr2	42553239	ALK	chr2	29446626
COSMIC	1146765	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1146766	EML4	chr2	42524141	ALK	chr2	29447648
COSMIC	1146953	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1146954	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1146955	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1146956	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1146957	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1146958	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1146959	EML4	chr2	42530369	ALK	chr2	29446394
COSMIC	1146960	EML4	chr2	42530369	ALK	chr2	29446394
COSMIC	1147270	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1147271	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1147272	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1147273	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1147396	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1147397	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1147398	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1163277	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1163278	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1163285	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1166407	EML4	chr2	42528532	ALK	chr2	29446345
COSMIC	1166408	EML4	chr2	42472827	ALK	chr2	29446511
COSMIC	1177253	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1177254	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1177255	EML4	chr2	42552876	ALK	chr2	29446461
COSMIC	1177256	EML4	chr2	42543844	ALK	chr2	29446566
COSMIC	1177257	EML4	chr2	42492676	ALK	chr2	29446509
COSMIC	1177258	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1177259	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1177260	EML4	chr2	42523103	ALK	chr2	29446555
COSMIC	1177261	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1177262	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1177263	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1177264	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1177265	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1178187	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1178188	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1178189	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1178190	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1178191	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1178192	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1178193	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1178194	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1178195	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1214897	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1214899	EML4	chr2	42522656	ALK	chr2	29446463
COSMIC	1214900	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1214901	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1214902	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1214903	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1214904	EML4	chr2	42528532	ALK	chr2	29446394
COSMIC	1305533	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1305534	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1305535	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1305536	EML4	chr2	42552694	ALK	chr2	29446412
COSMIC	1305537	EML4	chr2	42531691	ALK	chr2	29446394
COSMIC	1311456	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1311457	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1434759	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1436069	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1436070	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1436071	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1436072	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1436073	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1436074	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1436075	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1436076	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1436077	EML4	chr2	42472827	ALK	chr2	29446511
COSMIC	1436078	EML4	chr2	42543844	ALK	chr2	29446566
COSMIC	1436079	EML4	chr2	42543844	ALK	chr2	29446566
COSMIC	1436080	EML4	chr2	42543844	ALK	chr2	29446566
COSMIC	1451169	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1451170	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1451171	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1484503	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1484504	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1484505	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1484506	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1484507	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1484508	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1484509	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1489401	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1489534	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1534666	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1548057	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1548824	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1548825	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1548826	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1548833	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1548834	EML4	chr2	42528532	ALK	chr2	29446394
COSMIC	1549203	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1606146	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606147	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606148	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606149	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606150	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606151	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606152	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606153	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606154	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606155	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606156	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606157	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606158	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606159	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606160	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606161	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606162	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606163	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606164	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606165	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606166	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606167	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606168	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606169	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1606170	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1606171	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1606172	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1606173	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1606174	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1606175	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1606176	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1606177	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1606178	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1606179	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1606180	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1606181	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1606182	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1612227	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1612228	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1630246	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1630247	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1630248	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1630249	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1630250	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1630251	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1630252	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1630253	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1630254	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1630255	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1630256	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1630257	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1632940	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1632941	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1632942	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1632943	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1632944	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1632945	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1632946	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1632947	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1632948	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1632949	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1677599	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1705460	EML4	chr2	42491871	ALK	chr2	29448431
COSMIC	1713304	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1713305	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1713306	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1713307	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1713308	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1713309	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1713310	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1713311	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1793000	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1793001	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1793002	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1793003	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1793005	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1793006	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1803421	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1816762	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1822543	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1822544	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1822545	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1822546	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1822547	EML4	chr2	42534213	ALK	chr2	29446348
COSMIC	1843291	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843292	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843293	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843294	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843295	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843296	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843297	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843298	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843299	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843300	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843301	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843302	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843303	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843304	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1843305	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1843306	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1843307	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1843308	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1843309	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1843310	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1843311	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1843312	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1843313	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1843314	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1843315	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1843316	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1843317	EML4	chr2	42543190	ALK	chr2	29446394
COSMIC	1843318	EML4	chr2	42543190	ALK	chr2	29446394
COSMIC	1859880	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1859882	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1859883	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1859884	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1859885	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1859886	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1859887	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1859889	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1859890	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1859891	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1859892	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1876360	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1876361	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1876362	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1876363	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1876364	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1876365	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1876366	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1876367	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1876368	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1876369	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1876370	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1877570	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1877571	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1877572	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1877573	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	1881933	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1881934	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1881935	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1881936	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1881937	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1881938	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1881939	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	1885247	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1960289	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1967588	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	1994483	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1994484	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1994485	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1994486	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1994487	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	1994488	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2018657	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2018658	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2018716	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2028264	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2028265	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2028266	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2028267	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2028268	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2028269	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2028270	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	2028271	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	2028272	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2046669	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2046670	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2069164	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2069215	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2069216	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2069217	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2081996	EML4	chr2	42522656	ALK	chr2	29446484
COSMIC	2081997	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2081998	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2081999	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2082000	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2082001	EML4	chr2	42472827	ALK	chr2	29446394
COSMIC	2082004	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2082005	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2082006	EML4	chr2	42528532	ALK	chr2	29446517
COSMIC	2082008	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2083487	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2083489	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2083490	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2085493	EML4	chr2	42491871	ALK	chr2	29446412
COSMIC	2085494	EML4	chr2	42491871	ALK	chr2	29446412
COSMIC	2144805	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	2144806	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	2148699	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2148700	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2148701	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2148702	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2148703	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2148704	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2148705	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2163063	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2163064	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2163065	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	2163066	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2163067	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2163068	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2180805	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208162	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208163	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208164	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208165	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208166	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208167	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208168	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208169	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208170	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208171	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208172	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208173	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208174	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208175	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208176	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208177	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208178	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208179	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208180	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208181	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208182	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208183	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208184	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208185	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208186	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208187	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208188	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208189	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208190	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208191	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2208192	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2208193	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2208194	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2208195	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2208196	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2208197	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2208198	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2208199	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2208200	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208201	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208202	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208203	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208204	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208205	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208206	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208207	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208208	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208209	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208210	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208211	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208212	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208213	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208214	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208215	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208216	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208217	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208218	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208219	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208220	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208221	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208222	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2208223	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2227460	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2293726	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2293727	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2293728	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2293729	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	2293730	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	2361994	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2361995	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2432353	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2432354	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2522064	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2522065	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2522066	EML4	chr2	42543190	ALK	chr2	29446394
COSMIC	2522067	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2522068	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2522069	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	2522070	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	2559425	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2559426	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2624130	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	2763253	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	2763254	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	2763255	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	2763256	EML4	chr2	42491871	ALK	chr2	29446394
COSMIC	AYA09	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	BR0009	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	BR0052	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	DFCI032	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	FA34	EML4	chr2	42552694	ALK	chr2	29446394
COSMIC	H2228	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	H3122-CHR-A1	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	H3122	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	HC2228	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	LU-01-0319	EML4	chr2	42492091	ALK	chr2	29446394
COSMIC	NCI-H3122-CR1	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	NSCLC063	EML4	chr2	42522656	ALK	chr2	29446394
COSMIC	SNU-2535	EML4	chr2	42522656	ALK	chr2	29446394
CCLE	C10	EML4	chr2	42522656	ALK	chr2	29446394
CCLE	HS-PSS	EML4	chr2	42472827	ALK	chr2	29446394
CCLE	HS-PSS	EML4	chr2	42472827	ALK	chr2	29447544
CCLE	NCI-H2228	EML4	chr2	42491871	ALK	chr2	29446394
CCLE	NCI-H2228	EML4	chr2	42492091	ALK	chr2	29446394
CCLE	NCI-H3122	EML4	chr2	42522656	ALK	chr2	29446394
CCLE	SNU-2535	EML4	chr2	42522656	ALK	chr2	29446394
CCLE	SNU-324	EML4	chr2	42491871	ALK	chr2	29446394
CCLE	SNU-324	EML4	chr2	42491871	ALK	chr2	29447544
CCLE	SNU-324	EML4	chr2	42492091	ALK	chr2	29446394
CCLE	SNU-324	EML4	chr2	42492091	ALK	chr2	29447544

Statistics of # Sampled Expressed This Fusion Gene Across Four Resources.

X-axis: resources, Y-axis: # samples

Fusion Gene and Drug/Small Molecule Search from PubMed Abstracts

PubMed Abstract Search With ['A-B' AND 'drug'], ['A::B' AND 'drug'].
*We used all combinations of gene synonyms of both partner genes and all combinations of ~ 14K drugs/small molecules in three categories of libraries (05-30-2024)

Statistics of the Found Drugs/Small Molecules.

PMID	Fusion Gene Name	Drug	Study Title
34633654	EML4-ALK1	Crizotinib	F-circEA1 regulates cell proliferation and apoptosis through ALK downstream signaling pathway in non-small cell lung cancer.
26992917	EML4-ALK	Afatinib	Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
33935502	EML4-ALK	Afatinib	EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report.
22085575	EML4-ALK	Afatinib	[New 'targeted therapy' for lung cancer].
22703830	EML4-ALK	Afatinib	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
28210128	EML4-ALK	Afatinib	Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.
26682573	EML4-ALK	Afatinib	Activation of EGFR Bypass Signaling by TGFÎ± Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.
33091968	EML4-ALK	Alectinib	A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation.
32558295	EML4-ALK	Alectinib	Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.
35116617	EML4-ALK	Alectinib	Complex genetic alterations contribute to rapid disease progression in an ALK rearrangement lung adenocarcinoma patient: a case report.
28101031	EML4-ALK	Alectinib	Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer.
25096400	EML4-ALK	Alectinib	Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
33128468	EML4-ALK	Alectinib	Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor.
26171201	EML4-ALK	Alectinib	Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report.
30069772	EML4-ALK	Alectinib	Alectinib.
33489815	EML4-ALK	Alectinib	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).
37384219	EML4-ALK	Alectinib	Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report.
33627640	EML4-ALK	Alectinib	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
29808239	EML4-ALK	Alectinib	Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
34548910	EML4-ALK	Alectinib	Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition.
30074936	EML4-ALK	Alectinib	Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
34661367	EML4-ALK	Alectinib	Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.
35579989	EML4-ALK	Alectinib	"Special issue ""The advance of solid tumor research in China"": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China."
25876560	EML4-ALK	Alectinib	Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
36207130	EML4-ALK	Alectinib	Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
29610932	EML4-ALK	Alectinib	EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib.
26327925	EML4-ALK	Alectinib	Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.
34064158	EML4-ALK	Alectinib	Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report.
37055606	EML4-ALK	Alectinib	Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report.
34763318	EML4-ALK	Alectinib	A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
32819126	EML4-ALK	Alectinib	An ALK-positive lung adenocarcinoma with gastric and skin metastasis: a case report and literature review.
30071258	EML4-ALK	Alectinib	Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.
27491402	EML4-ALK	Alectinib	EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.
24952482	EML4-ALK	Alectinib	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
30133144	EML4-ALK	Alectinib	Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
25819217	EML4-ALK	Alectinib	[Second generation ALK inhibitors in non-small cell lung cancer: systemic review].
32409002	EML4-ALK	Alectinib	A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.
36099717	EML4-ALK	Alectinib	Confirmation of lung adenocarcinoma as the primary cancer with detection of EML4-ALK rearrangement using next-generation sequencing: a case study.
37255276	EML4-ALK	Alectinib	Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.
35350512	EML4-ALK	Alectinib	Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA.
26992917	EML4-ALK	Alectinib	Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
30902613	EML4-ALK	Alectinib	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of AlectinibÂ inÂ Untreated ALK-Positive Advanced Non-Small CellÂ Lung Cancer in the Global Phase III ALEX Study.
38023218	EML4-ALK	Alectinib	Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.
25205428	EML4-ALK	Alectinib	Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
26200283	EML4-ALK	Alectinib	A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib.
27783866	EML4-ALK	Alectinib	Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
31971859	EML4-ALK	Alectinib	Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.
34520436	EML4-ALK	Alectinib	Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells.
38360931	EML4-ALK	Alectinib	Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
35927049	EML4-ALK	Alectinib	[Multiple pulmonary nodules with interstitial changes].
25971657	EML4-ALK	Alectinib	The EML4-ALK oncogene: targeting an essential growth driver in human cancer.
36132152	EML4-ALK	Alectinib	EML4-ALK rearrangement in primary malignant fibrous histiocytoma of the lung treated with alectinib: A case report.
34590027	EML4-ALK	Alectinib	EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report.
26682573	EML4-ALK	Alectinib	Activation of EGFR Bypass Signaling by TGFÎ± Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.
31305295	EML4-ALK	Alectinib	Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
32620470	EML4-ALK	Alectinib	EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature.
36728908	EML4-ALK	Alectinib	Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
25727400	EML4-ALK	Alectinib	Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
32850382	EML4-ALK	Alectinib	Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report.
38380327	EML4-ALK	Alectinib	Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
38213097	EML4-ALK	Alectinib	A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.
34763158	EML4-ALK	Alectinib	Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
34589977	EML4-ALK	Alectinib	A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.
26719536	EML4-ALK	Alectinib	Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
32600123	EML4-ALK	Alectinib	Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
35946559	EML4-ALK	Alectinib	A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis.
36612200	EML4-ALK	Alectinib	Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).
25806325	EML4-ALK	Alectinib	Ceritinib as a promising therapy for ALK related diseases.
33776709	EML4-ALK	Alectinib	Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature.
33906872	EML4-ALK	Alectinib	EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
35070986	EML4-ALK	Alectinib	Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy.
24598368	EML4-ALK	Alectinib	Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
34159737	EML4-ALK	Alectinib	A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4â€‰years by switching to ceritinib.
33489810	EML4-ALK	Alectinib	A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer.
25393796	EML4-ALK	Alectinib	Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
31033499	EML4-ALK	Alectinib	Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
37187318	EML4-ALK	Alectinib	From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
36927974	EML4-ALK	Alectinib	Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.
24887559	EML4-ALK	Alectinib	Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
37007089	EML4-ALK	Alectinib	Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report.
32397295	EML4-ALK	Alectinib	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
38027370	EML4-ALK	Alectinib	Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung Cancer.
37663243	EML4-ALK	Alectinib	Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy.
30171175	EML4-ALK	Alectinib	Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
28077299	EML4-ALK	Alectinib	Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
25581823	EML4-ALK	Alectinib	In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
36688904	EML4-ALK	Alectinib	Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
32845005	EML4-ALK	Alectinib	EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
27405684	EML4-ALK	Alectinib	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
31766077	EML4-ALK	Alectinib	Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
33484069	EML4-ALK	Alectinib	Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level.
37082099	EML4-ALK	Alectinib	Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion.
36387181	EML4-ALK	Alectinib	ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review.
26654422	EML4-ALK	Alectinib	Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
36739466	EML4-ALK	Alectinib	Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity.
33494549	EML4-ALK	Alectinib	Therapeutic Sequencing in ALK+ NSCLC.
37434391	EML4-ALK	Alectinib	Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
37899398	EML4-ALK	Alectinib	A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
36072009	EML4-ALK	Alectinib	Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report.
33352844	EML4-ALK	Alectinib	The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
37907052	EML4-ALK	Alectinib	Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
32558295	EML4-ALK	Alvocidib	Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.
36072009	EML4-ALK	Anlotinib	Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report.
38027370	EML4-ALK	ATP	Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung Cancer.
37036171	EML4-ALK	ATP	Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions.
22703830	EML4-ALK	AUY922	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
24598368	EML4-ALK	AUY922	Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
22703830	EML4-ALK	Axitinib	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
23052178	EML4-ALK	Azathioprine	EML4-ALK-positive non-small cell lung cancer in a patient treated with azathioprine for ulcerative colitis.
32179332	EML4-ALK	Brigatinib	Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.
36096442	EML4-ALK	Brigatinib	Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
33380260	EML4-ALK	Brigatinib	The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.
37647220	EML4-ALK	Brigatinib	Synthesis and Preclinical Evaluation of [Methylpiperazine-11C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase.
36922348	EML4-ALK	Brigatinib	Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib.
33489815	EML4-ALK	Brigatinib	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).
38521003	EML4-ALK	Brigatinib	Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome.
34548910	EML4-ALK	Brigatinib	Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition.
31971859	EML4-ALK	Brigatinib	Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.
28628492	EML4-ALK	Brigatinib	Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient.
38360931	EML4-ALK	Brigatinib	Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
26654422	EML4-ALK	Brigatinib	Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
36207130	EML4-ALK	Brigatinib	Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
34159737	EML4-ALK	Brigatinib	A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4â€‰years by switching to ceritinib.
33494549	EML4-ALK	Brigatinib	Therapeutic Sequencing in ALK+ NSCLC.
35235872	EML4-ALK	Brigatinib	Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation.
30679319	EML4-ALK	Brigatinib	Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors.
37434391	EML4-ALK	Brigatinib	Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
31033499	EML4-ALK	Brigatinib	Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
37187318	EML4-ALK	Brigatinib	From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
33352844	EML4-ALK	Brigatinib	The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
31305295	EML4-ALK	Brigatinib	Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
22690483	EML4-ALK	Capecitabine	[Will targeted therapies replace chemotherapy?].
34034462	EML4-ALK	Carboplatin	[A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors â€©and Chemotherapy].
35350512	EML4-ALK	Carboplatin	Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA.
37384219	EML4-ALK	Carboplatin	Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report.
33225619	EML4-ALK	Carboplatin	Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway.
23254266	EML4-ALK	Carboplatin	Lung cancer and pregnancy.
23769349	EML4-ALK	Carboplatin	[Long-term survival of a patient with advanced non-small cell lung cancer on bevacizumab therapy: case report and review of the literature].
36207130	EML4-ALK	Carboplatin	Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
31118683	EML4-ALK	Cefoperazone	Poor prognosis of pulmonary sarcomatoid carcinoma with KRAS mutation and ALK fusion.
34034462	EML4-ALK	Ceritinib	[A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors â€©and Chemotherapy].
32558295	EML4-ALK	Ceritinib	Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.
29458018	EML4-ALK	Ceritinib	5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downstream pathways in Karpas299 and H2228â€¯cells.
33878728	EML4-ALK	Ceritinib	Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
33907223	EML4-ALK	Ceritinib	ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells.
33489815	EML4-ALK	Ceritinib	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).
30075548	EML4-ALK	Ceritinib	Organizing pneumonia resembling disease progression in a non-small-cell lung cancer patient receiving ceritinib: A case report.
37116853	EML4-ALK	Ceritinib	ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228Â cells.
34661367	EML4-ALK	Ceritinib	Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.
36207130	EML4-ALK	Ceritinib	Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
26327925	EML4-ALK	Ceritinib	Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.
26775591	EML4-ALK	Ceritinib	A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
30071258	EML4-ALK	Ceritinib	Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.
25489176	EML4-ALK	Ceritinib	Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer.
26923554	EML4-ALK	Ceritinib	Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer.
25819217	EML4-ALK	Ceritinib	[Second generation ALK inhibitors in non-small cell lung cancer: systemic review].
26775573	EML4-ALK	Ceritinib	[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
26992917	EML4-ALK	Ceritinib	Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
34754197	EML4-ALK	Ceritinib	Long-Term Survival After Salvage Thoracic Surgery on a Patient with ALK-Rearranged Metastatic Lung Adenocarcinoma After Progression on Targeted Therapy.
37105002	EML4-ALK	Ceritinib	Discovery of a miniaturized PROTAC with potent activity and high selectivity.
30274779	EML4-ALK	Ceritinib	Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
27507192	EML4-ALK	Ceritinib	Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.
27783866	EML4-ALK	Ceritinib	Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
38327793	EML4-ALK	Ceritinib	A small-molecule degrader selectively inhibits the growth of ALK-rearranged lung cancer with ceritinib resistance.
31971859	EML4-ALK	Ceritinib	Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.
28528303	EML4-ALK	Ceritinib	Discovery of a potent dual ALK and EGFR T790M inhibitor.
38360931	EML4-ALK	Ceritinib	Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
25971657	EML4-ALK	Ceritinib	The EML4-ALK oncogene: targeting an essential growth driver in human cancer.
31305295	EML4-ALK	Ceritinib	Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
29732013	EML4-ALK	Ceritinib	Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein.
32227409	EML4-ALK	Ceritinib	In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
29284707	EML4-ALK	Ceritinib	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.
32184963	EML4-ALK	Ceritinib	Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer.
36750097	EML4-ALK	Ceritinib	Piperlongumine conjugates induce targeted protein degradation.
25806325	EML4-ALK	Ceritinib	Ceritinib as a promising therapy for ALK related diseases.
26622190	EML4-ALK	Ceritinib	Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib.
32344689	EML4-ALK	Ceritinib	ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation.
29290262	EML4-ALK	Ceritinib	GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
34159737	EML4-ALK	Ceritinib	A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4â€‰years by switching to ceritinib.
37187318	EML4-ALK	Ceritinib	From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
32340536	EML4-ALK	Ceritinib	Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient.
36096442	EML4-ALK	Ceritinib	Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
38027370	EML4-ALK	Ceritinib	Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung Cancer.
28077299	EML4-ALK	Ceritinib	Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
35085771	EML4-ALK	Ceritinib	EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
26654422	EML4-ALK	Ceritinib	Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
29327716	EML4-ALK	Ceritinib	Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.
33352844	EML4-ALK	Ceritinib	The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
31633304	EML4-ALK	Cerivastatin	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer.
36096442	EML4-ALK	Creatine	Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
22617245	EML4-ALK	Crizotinib	Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
25626064	EML4-ALK	Crizotinib	Lung cancer mutations and use of targeted agents in Hispanics.
33091968	EML4-ALK	Crizotinib	A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation.
34034462	EML4-ALK	Crizotinib	[A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors â€©and Chemotherapy].
35116617	EML4-ALK	Crizotinib	Complex genetic alterations contribute to rapid disease progression in an ALK rearrangement lung adenocarcinoma patient: a case report.
28373815	EML4-ALK	Crizotinib	Systemic treatment of non-small cell lung cancer brain metastases.
33878728	EML4-ALK	Crizotinib	Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
35852680	EML4-ALK	Crizotinib	Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
30075548	EML4-ALK	Crizotinib	Organizing pneumonia resembling disease progression in a non-small-cell lung cancer patient receiving ceritinib: A case report.
33466277	EML4-ALK	Crizotinib	NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target.
26666609	EML4-ALK	Crizotinib	Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
21288922	EML4-ALK	Crizotinib	Targeting anaplastic lymphoma kinase in lung cancer.
33225619	EML4-ALK	Crizotinib	Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway.
32527613	EML4-ALK	Crizotinib	Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
24102046	EML4-ALK	Crizotinib	Presence of anaplastic lymphoma kinase in inflammatory breast cancer.
24565582	EML4-ALK	Crizotinib	Extending survival of stage IV non-small cell lung cancer.
27926526	EML4-ALK	Crizotinib	Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
34630126	EML4-ALK	Crizotinib	LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis.
24419120	EML4-ALK	Crizotinib	Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
24001942	EML4-ALK	Crizotinib	Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
29997961	EML4-ALK	Crizotinib	The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer.
23788933	EML4-ALK	Crizotinib	Crizotinib in the treatment of non-small-cell lung carcinoma.
26045865	EML4-ALK	Crizotinib	Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
27783866	EML4-ALK	Crizotinib	Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
22797152	EML4-ALK	Crizotinib	Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib.
22690483	EML4-ALK	Crizotinib	[Will targeted therapies replace chemotherapy?].
22932897	EML4-ALK	Crizotinib	The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
35116907	EML4-ALK	Crizotinib	Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib.
35927049	EML4-ALK	Crizotinib	[Multiple pulmonary nodules with interstitial changes].
25971657	EML4-ALK	Crizotinib	The EML4-ALK oncogene: targeting an essential growth driver in human cancer.
29535536	EML4-ALK	Crizotinib	Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion.
31305295	EML4-ALK	Crizotinib	Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
33227290	EML4-ALK	Crizotinib	The effect of metformin in EML4-ALK+Â lung cancer alone and in combination with crizotinib in cell and rodent models.
37254687	EML4-ALK	Crizotinib	Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in ALK-positive non-small-cell lung cancer.
23052178	EML4-ALK	Crizotinib	EML4-ALK-positive non-small cell lung cancer in a patient treated with azathioprine for ulcerative colitis.
24688086	EML4-ALK	Crizotinib	Secondary EML4-ALK-positive lung adenocarcinoma in a patient previously treated for acute lymphoblastic leukemia in childhood: a case report.
29951342	EML4-ALK	Crizotinib	Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.
27366096	EML4-ALK	Crizotinib	Bilateral breast adenocarcinomas with EML4-ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?
30791979	EML4-ALK	Crizotinib	miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
25393796	EML4-ALK	Crizotinib	Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
30679319	EML4-ALK	Crizotinib	Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors.
24616318	EML4-ALK	Crizotinib	Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.
31033499	EML4-ALK	Crizotinib	Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
23443800	EML4-ALK	Crizotinib	ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
32340536	EML4-ALK	Crizotinib	Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient.
24887559	EML4-ALK	Crizotinib	Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
27141364	EML4-ALK	Crizotinib	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1Î± and STAT3.
22614968	EML4-ALK	Crizotinib	Personalized targeted therapy in advanced non-small cell lung cancer.
23533265	EML4-ALK	Crizotinib	Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
21220230	EML4-ALK	Crizotinib	[Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer].
26107243	EML4-ALK	Crizotinib	A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer.
25601488	EML4-ALK	Crizotinib	Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.
38027370	EML4-ALK	Crizotinib	Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung Cancer.
23394083	EML4-ALK	Crizotinib	New molecular targets in the treatment of NSCLC.
28039177	EML4-ALK	Crizotinib	Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
38599812	EML4-ALK	Crizotinib	[A case of crizotinib-associated renal cysts].
33470536	EML4-ALK	Crizotinib	Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
35117067	EML4-ALK	Crizotinib	EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy.
26517679	EML4-ALK	Crizotinib	Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
22703830	EML4-ALK	Crizotinib	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
21428883	EML4-ALK	Crizotinib	Targeted therapies and other agents as first-line maintenance and beyond: particular benefit in pulmonary adenocarcinoma patients.
37434391	EML4-ALK	Crizotinib	Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
31010733	EML4-ALK	Crizotinib	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.
27863497	EML4-ALK	Crizotinib	Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report.
25101240	EML4-ALK	Crizotinib	A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer.
24156959	EML4-ALK	Crizotinib	Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
26142544	EML4-ALK	Crizotinib	Droplet Digital PCR for Absolute Quantification ofÂ EML4-ALK Gene Rearrangement in Lung Adenocarcinoma.
23328551	EML4-ALK	Crizotinib	Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer.
33844110	EML4-ALK	Crizotinib	Are all ALK variants created equal? Clinicopathologic features and outcomes: a propensity-matched study.
23226067	EML4-ALK	Crizotinib	Personalized medicine and treatment approaches in non-small-cell lung carcinoma.
27458283	EML4-ALK	Crizotinib	Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?
36369474	EML4-ALK	Crizotinib	Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling.
23325296	EML4-ALK	Crizotinib	ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
27663401	EML4-ALK	Crizotinib	A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
32819126	EML4-ALK	Crizotinib	An ALK-positive lung adenocarcinoma with gastric and skin metastasis: a case report and literature review.
26134230	EML4-ALK	Crizotinib	Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
26923554	EML4-ALK	Crizotinib	Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer.
32878782	EML4-ALK	Crizotinib	ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer.
25941796	EML4-ALK	Crizotinib	Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.
25819217	EML4-ALK	Crizotinib	[Second generation ALK inhibitors in non-small cell lung cancer: systemic review].
29444468	EML4-ALK	Crizotinib	A major component of vitamin E, Î±-tocopherol inhibits the anti-tumor activity of crizotinib against cells transformed by EML4-ALK.
31027700	EML4-ALK	Crizotinib	Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
25806283	EML4-ALK	Crizotinib	Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.
23750540	EML4-ALK	Crizotinib	Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.
23169500	EML4-ALK	Crizotinib	Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.
25678804	EML4-ALK	Crizotinib	Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.
27507192	EML4-ALK	Crizotinib	Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.
23910397	EML4-ALK	Crizotinib	Lung cancer during pregnancy: an unusual case.
22594847	EML4-ALK	Crizotinib	Crizotinib in the treatment of non-small-cell lung cancer.
31971859	EML4-ALK	Crizotinib	Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.
24885608	EML4-ALK	Crizotinib	Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy.
23769348	EML4-ALK	Crizotinib	[Clinical research of crizotinib in advanced non-small cell lung cancer].
38360931	EML4-ALK	Crizotinib	Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
23254266	EML4-ALK	Crizotinib	Lung cancer and pregnancy.
27237027	EML4-ALK	Crizotinib	TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.
34552337	EML4-ALK	Crizotinib	High Tumor Mutation Burden and DNA Repair Gene Mutations are Associated with Primary Resistance to Crizotinib in ALK-Rearranged Lung Cancer.
34164217	EML4-ALK	Crizotinib	WBRT for brain metastases from non-small cell lung cancer: for whom and when?-Contemporary point of view.
30225407	EML4-ALK	Crizotinib	A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing-Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib.
24992725	EML4-ALK	Crizotinib	Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
21475126	EML4-ALK	Crizotinib	New targets in advanced NSCLC: EML4-ALK.
26719536	EML4-ALK	Crizotinib	Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
24022905	EML4-ALK	Crizotinib	Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer.
32344689	EML4-ALK	Crizotinib	ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation.
31401883	EML4-ALK	Crizotinib	Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors.
27637025	EML4-ALK	Crizotinib	ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country.
33348616	EML4-ALK	Crizotinib	Lung Adenocarcinoma Mouse Models Based on Orthotopic Transplantation of Syngeneic Tumor-Initiating Cells Expressing EpCAM, SCA-1, and Ly6d.
29950868	EML4-ALK	Crizotinib	lincROR influences the stemness and crizotinib resistance in EML-ALK+ non-small-cell lung cancer cells.
33489810	EML4-ALK	Crizotinib	A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer.
25785456	EML4-ALK	Crizotinib	Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods.
29091425	EML4-ALK	Crizotinib	Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.
36730620	EML4-ALK	Crizotinib	First-line crizotinib therapy is effective for a novel SEC31A-anaplastic lymphoma kinase fusion in a patient with stage IV lung adenocarcinoma: a case report and literature reviews.
25247338	EML4-ALK	Crizotinib	NSCLC and HER2: between lights and shadows.
23785245	EML4-ALK	Crizotinib	Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.
33307508	EML4-ALK	Crizotinib	Prolonged survival without progression under crizotinib treatment.
23301645	EML4-ALK	Crizotinib	[EML4-ALK fusion gene in patients with lung carcinoma: biology, diagnostics and targeted therapy].
27804873	EML4-ALK	Crizotinib	Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer.
21504625	EML4-ALK	Crizotinib	Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
22443647	EML4-ALK	Crizotinib	Personalized therapy for non-small cell lung cancer: which drug for which patient?
25592111	EML4-ALK	Crizotinib	Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.
25581823	EML4-ALK	Crizotinib	In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
24649213	EML4-ALK	Crizotinib	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation.
26654422	EML4-ALK	Crizotinib	Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
30069759	EML4-ALK	Crizotinib	Crizotinib.
34590916	EML4-ALK	Crizotinib	A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report.
37899398	EML4-ALK	Crizotinib	A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
30381078	EML4-ALK	Crizotinib	CT-707 Overcomes Resistance of Crizotinib through Activating PDPK1- AKT1 Pathway by Targeting FAK.
33363027	EML4-ALK	Crizotinib	Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer.
35433411	EML4-ALK	Crizotinib	Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report.
23741400	EML4-ALK	Crizotinib	Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.
32558295	EML4-ALK	Crizotinib	Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.
25096400	EML4-ALK	Crizotinib	Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
27078848	EML4-ALK	Crizotinib	CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma.
24486291	EML4-ALK	Crizotinib	Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.
31521978	EML4-ALK	Crizotinib	The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
26171201	EML4-ALK	Crizotinib	Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report.
30069772	EML4-ALK	Crizotinib	Alectinib.
25349124	EML4-ALK	Crizotinib	Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
33489815	EML4-ALK	Crizotinib	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).
24940496	EML4-ALK	Crizotinib	Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
25562798	EML4-ALK	Crizotinib	Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.
30068733	EML4-ALK	Crizotinib	Endometrial cancer with an EML4-ALK rearrangement.
25876560	EML4-ALK	Crizotinib	Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
29184678	EML4-ALK	Crizotinib	Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared.
36207130	EML4-ALK	Crizotinib	Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
26327925	EML4-ALK	Crizotinib	Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.
31118683	EML4-ALK	Crizotinib	Poor prognosis of pulmonary sarcomatoid carcinoma with KRAS mutation and ALK fusion.
26775591	EML4-ALK	Crizotinib	A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
28210128	EML4-ALK	Crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.
23486270	EML4-ALK	Crizotinib	Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement.
30071258	EML4-ALK	Crizotinib	Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.
21156280	EML4-ALK	Crizotinib	ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.
36099717	EML4-ALK	Crizotinib	Confirmation of lung adenocarcinoma as the primary cancer with detection of EML4-ALK rearrangement using next-generation sequencing: a case study.
34754197	EML4-ALK	Crizotinib	Long-Term Survival After Salvage Thoracic Surgery on a Patient with ALK-Rearranged Metastatic Lung Adenocarcinoma After Progression on Targeted Therapy.
25929953	EML4-ALK	Crizotinib	Therapeutic management of ALK+ nonsmall cell lung cancer patients.
30902613	EML4-ALK	Crizotinib	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of AlectinibÂ inÂ Untreated ALK-Positive Advanced Non-Small CellÂ Lung Cancer in the Global Phase III ALEX Study.
26788139	EML4-ALK	Crizotinib	EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer.
33816312	EML4-ALK	Crizotinib	Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer.
31924369	EML4-ALK	Crizotinib	Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
22435662	EML4-ALK	Crizotinib	Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
23993685	EML4-ALK	Crizotinib	Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation.
28628492	EML4-ALK	Crizotinib	Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient.
24199682	EML4-ALK	Crizotinib	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
22999080	EML4-ALK	Crizotinib	Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.
25788996	EML4-ALK	Crizotinib	Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report.
26168728	EML4-ALK	Crizotinib	Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins.
23201355	EML4-ALK	Crizotinib	Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
26412935	EML4-ALK	Crizotinib	Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer.
28781781	EML4-ALK	Crizotinib	Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.
25727400	EML4-ALK	Crizotinib	Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
29284707	EML4-ALK	Crizotinib	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.
34589977	EML4-ALK	Crizotinib	A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.
21767331	EML4-ALK	Crizotinib	Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
24019783	EML4-ALK	Crizotinib	Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer.
28407036	EML4-ALK	Crizotinib	The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer.
23324244	EML4-ALK	Crizotinib	[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].
24598368	EML4-ALK	Crizotinib	Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
23664446	EML4-ALK	Crizotinib	EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report.
30171175	EML4-ALK	Crizotinib	Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
24567430	EML4-ALK	Crizotinib	Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
25178493	EML4-ALK	Crizotinib	Activity of crizotinib over choroidal metastases in non-small-cell lung cancer (NSCLC)-ALK rearranged: a case report.
25588859	EML4-ALK	Crizotinib	Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
27202302	EML4-ALK	Crizotinib	The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer.
33494549	EML4-ALK	Crizotinib	Therapeutic Sequencing in ALK+ NSCLC.
26295973	EML4-ALK	Crizotinib	Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
25170107	EML4-ALK	Crizotinib	A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
23918070	EML4-ALK	Crizotinib	Second-Line Therapy for Advanced NSCLC.
29776229	EML4-ALK	Crizotinib	Epidemiology of EML4-ALK translocations in a small, German non-small-cell lung cancer patient cohort.
23731739	EML4-ALK	Crizotinib	A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene.
33444901	EML4-ALK	Crizotinib	Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
30368411	EML4-ALK	Crizotinib	Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib.
32974126	EML4-ALK	Crizotinib	Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055).
24070465	EML4-ALK	Crizotinib	Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents.
37064118	EML4-ALK	Crizotinib	Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib.
34373943	EML4-ALK	Crizotinib	Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC.
22568572	EML4-ALK	Crizotinib	Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.
37647220	EML4-ALK	Crizotinib	Synthesis and Preclinical Evaluation of [Methylpiperazine-11C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase.
29650534	EML4-ALK	Crizotinib	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
24828670	EML4-ALK	Crizotinib	A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib.
25489176	EML4-ALK	Crizotinib	Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer.
27341790	EML4-ALK	Crizotinib	Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer.
35999455	EML4-ALK	Crizotinib	Crizotinib attenuates cancer metastasis by inhibiting TGFÎ² signaling in non-small cell lung cancer cells.
25408655	EML4-ALK	Crizotinib	A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib.
31564978	EML4-ALK	Crizotinib	Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib.
24419060	EML4-ALK	Crizotinib	The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
26775573	EML4-ALK	Crizotinib	[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
26992917	EML4-ALK	Crizotinib	Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
33380260	EML4-ALK	Crizotinib	The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.
35822498	EML4-ALK	Crizotinib	A new approach used in docking study for predicting the combination drug efficacy in EML4-ALK target of NSCLC.
35277956	EML4-ALK	Crizotinib	Reassessing pharmacogenomic cell sensitivity with multilevel statistical models.
24992173	EML4-ALK	Crizotinib	ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma.
27045755	EML4-ALK	Crizotinib	Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.
23951022	EML4-ALK	Crizotinib	Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
34845836	EML4-ALK	Crizotinib	A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.
22553343	EML4-ALK	Crizotinib	Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
31388026	EML4-ALK	Crizotinib	Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.
26137041	EML4-ALK	Crizotinib	Primary signet-ring cell carcinoma of the lung treated with crizotinib: A case report.
23254764	EML4-ALK	Crizotinib	Effect of PF-02341066 and radiation on non-small cell lung cancer cells.
22787411	EML4-ALK	Crizotinib	Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.
21502504	EML4-ALK	Crizotinib	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
31160357	EML4-ALK	Crizotinib	Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
38380327	EML4-ALK	Crizotinib	Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
23576200	EML4-ALK	Crizotinib	[Crizotinib - molecular therapy for lung cancer].
31122560	EML4-ALK	Crizotinib	Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib.
33896729	EML4-ALK	Crizotinib	A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib.
22986231	EML4-ALK	Crizotinib	Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
25806325	EML4-ALK	Crizotinib	Ceritinib as a promising therapy for ALK related diseases.
26622190	EML4-ALK	Crizotinib	Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib.
24756793	EML4-ALK	Crizotinib	Crizotinib.
29290262	EML4-ALK	Crizotinib	GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
22153831	EML4-ALK	Crizotinib	Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers.
24327273	EML4-ALK	Crizotinib	Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.
37187318	EML4-ALK	Crizotinib	From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
36927974	EML4-ALK	Crizotinib	Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.
34232939	EML4-ALK	Crizotinib	Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
25407901	EML4-ALK	Crizotinib	Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.
28077299	EML4-ALK	Crizotinib	Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
27405684	EML4-ALK	Crizotinib	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
29327716	EML4-ALK	Crizotinib	Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.
30290287	EML4-ALK	Crizotinib	MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report.
33352844	EML4-ALK	Crizotinib	The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
26544515	EML4-ALK	Crizotinib	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
25562798	EML4-ALK	Dabrafenib	Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.
25562798	EML4-ALK	Dacarbazine	Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.
27078848	EML4-ALK	Dasatinib	CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma.
32558295	EML4-ALK	Dinaciclib	Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.
33225619	EML4-ALK	Docetaxel	Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway.
37007089	EML4-ALK	Ensartinib	Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report.
33489815	EML4-ALK	Ensartinib	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).
37675235	EML4-ALK	Ensartinib	An unresectable and metastatic intrahepatic cholangiocarcinoma with EML4-ALK rearrangement achieving partial response after first-line treatment with ensartinib: a case report.
37187318	EML4-ALK	Ensartinib	From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
36730477	EML4-ALK	Ensartinib	Neoadjuvant target therapy with ensartinib in lung adenocarcinoma with EML4-ALK fusion variant: a case report and literature review.
33627640	EML4-ALK	Entrectinib	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
29054983	EML4-ALK	Entrectinib	ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.
23731739	EML4-ALK	Erlotinib	A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene.
22617245	EML4-ALK	Erlotinib	Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
25626064	EML4-ALK	Erlotinib	Lung cancer mutations and use of targeted agents in Hispanics.
28373815	EML4-ALK	Erlotinib	Systemic treatment of non-small cell lung cancer brain metastases.
24070465	EML4-ALK	Erlotinib	Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents.
25562798	EML4-ALK	Erlotinib	Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.
22085575	EML4-ALK	Erlotinib	[New 'targeted therapy' for lung cancer].
24565582	EML4-ALK	Erlotinib	Extending survival of stage IV non-small cell lung cancer.
28210128	EML4-ALK	Erlotinib	Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.
26775573	EML4-ALK	Erlotinib	[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
22620005	EML4-ALK	Erlotinib	[Diagnostic and therapeutic biomarkers for lung cancer patients].
26788139	EML4-ALK	Erlotinib	EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer.
22435662	EML4-ALK	Erlotinib	Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
25788996	EML4-ALK	Erlotinib	Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report.
24781527	EML4-ALK	Erlotinib	Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.
22787411	EML4-ALK	Erlotinib	Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.
20954328	EML4-ALK	Erlotinib	[Molecular targeted therapy in lung cancer].
24019783	EML4-ALK	Erlotinib	Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer.
27686809	EML4-ALK	Erlotinib	Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
23785245	EML4-ALK	Erlotinib	Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.
21168933	EML4-ALK	Erlotinib	EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
22614968	EML4-ALK	Erlotinib	Personalized targeted therapy in advanced non-small cell lung cancer.
22443647	EML4-ALK	Erlotinib	Personalized therapy for non-small cell lung cancer: which drug for which patient?
23394083	EML4-ALK	Erlotinib	New molecular targets in the treatment of NSCLC.
25407901	EML4-ALK	Erlotinib	Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.
24649213	EML4-ALK	Erlotinib	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation.
22703830	EML4-ALK	Erlotinib	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
21428883	EML4-ALK	Erlotinib	Targeted therapies and other agents as first-line maintenance and beyond: particular benefit in pulmonary adenocarcinoma patients.
31010733	EML4-ALK	Erlotinib	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.
23918070	EML4-ALK	Erlotinib	Second-Line Therapy for Advanced NSCLC.
35350512	EML4-ALK	Etoposide	Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA.
26295973	EML4-ALK	Fructose-6-phosphate	Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
24706829	EML4-ALK	Ganetespib	Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical Î²-propeller domain.
23533265	EML4-ALK	Ganetespib	Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
25626064	EML4-ALK	Gefitinib	Lung cancer mutations and use of targeted agents in Hispanics.
28373815	EML4-ALK	Gefitinib	Systemic treatment of non-small cell lung cancer brain metastases.
23178117	EML4-ALK	Gefitinib	MED12 controls the response to multiple cancer drugs through regulation of TGF-Î² receptor signaling.
24070465	EML4-ALK	Gefitinib	Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents.
25562798	EML4-ALK	Gefitinib	Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.
28210128	EML4-ALK	Gefitinib	Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.
24419120	EML4-ALK	Gefitinib	Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
26775573	EML4-ALK	Gefitinib	[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
22620005	EML4-ALK	Gefitinib	[Diagnostic and therapeutic biomarkers for lung cancer patients].
26788139	EML4-ALK	Gefitinib	EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer.
22690483	EML4-ALK	Gefitinib	[Will targeted therapies replace chemotherapy?].
22435662	EML4-ALK	Gefitinib	Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
28781781	EML4-ALK	Gefitinib	Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.
22787411	EML4-ALK	Gefitinib	Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.
36728908	EML4-ALK	Gefitinib	Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
20954328	EML4-ALK	Gefitinib	[Molecular targeted therapy in lung cancer].
25247338	EML4-ALK	Gefitinib	NSCLC and HER2: between lights and shadows.
27686809	EML4-ALK	Gefitinib	Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
23785245	EML4-ALK	Gefitinib	Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.
22614968	EML4-ALK	Gefitinib	Personalized targeted therapy in advanced non-small cell lung cancer.
21102267	EML4-ALK	Gefitinib	Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.
34232939	EML4-ALK	Gefitinib	Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
22443647	EML4-ALK	Gefitinib	Personalized therapy for non-small cell lung cancer: which drug for which patient?
23394083	EML4-ALK	Gefitinib	New molecular targets in the treatment of NSCLC.
25407901	EML4-ALK	Gefitinib	Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.
24649213	EML4-ALK	Gefitinib	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation.
36387181	EML4-ALK	Gefitinib	ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review.
23918070	EML4-ALK	Gefitinib	Second-Line Therapy for Advanced NSCLC.
20952506	EML4-ALK	Geldanamycin	Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
31370342	EML4-ALK	Geldanamycin	Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.
35852680	EML4-ALK	Gemcitabine	Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
33816312	EML4-ALK	Gemcitabine	Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer.
33627640	EML4-ALK	Gilteritinib	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
33225619	EML4-ALK	Gimeracil	Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway.
34763158	EML4-ALK	Hematoxylin	Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
22690483	EML4-ALK	Imatinib	[Will targeted therapies replace chemotherapy?].
37647220	EML4-ALK	Iodide	Synthesis and Preclinical Evaluation of [Methylpiperazine-11C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase.
33878728	EML4-ALK	Iodine	Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
22690483	EML4-ALK	Lapatinib	[Will targeted therapies replace chemotherapy?].
25489176	EML4-ALK	Lapatinib	Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer.
33878728	EML4-ALK	Lenvatinib	Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
22690483	EML4-ALK	Letrozole	[Will targeted therapies replace chemotherapy?].
34034462	EML4-ALK	Lorlatinib	[A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors â€©and Chemotherapy].
33878728	EML4-ALK	Lorlatinib	Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
33489815	EML4-ALK	Lorlatinib	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).
33627640	EML4-ALK	Lorlatinib	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
35852680	EML4-ALK	Lorlatinib	Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
34548910	EML4-ALK	Lorlatinib	Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition.
29650534	EML4-ALK	Lorlatinib	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
34887666	EML4-ALK	Lorlatinib	Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement.
37036171	EML4-ALK	Lorlatinib	Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions.
37934724	EML4-ALK	Lorlatinib	Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report.
34661367	EML4-ALK	Lorlatinib	Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.
36207130	EML4-ALK	Lorlatinib	Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
37255276	EML4-ALK	Lorlatinib	Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.
35350512	EML4-ALK	Lorlatinib	Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA.
33380260	EML4-ALK	Lorlatinib	The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.
32558067	EML4-ALK	Lorlatinib	ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.
28628492	EML4-ALK	Lorlatinib	Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient.
38360931	EML4-ALK	Lorlatinib	Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
34589977	EML4-ALK	Lorlatinib	A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.
32600123	EML4-ALK	Lorlatinib	Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
38433979	EML4-ALK	Lorlatinib	Overcoming Central Î²-Sheet #6 (CÎ²6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.
33906872	EML4-ALK	Lorlatinib	EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
30791979	EML4-ALK	Lorlatinib	miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
34159737	EML4-ALK	Lorlatinib	A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4â€‰years by switching to ceritinib.
31033499	EML4-ALK	Lorlatinib	Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
37187318	EML4-ALK	Lorlatinib	From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
29373100	EML4-ALK	Lorlatinib	Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
37007089	EML4-ALK	Lorlatinib	Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report.
31766077	EML4-ALK	Lorlatinib	Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
33494549	EML4-ALK	Lorlatinib	Therapeutic Sequencing in ALK+ NSCLC.
33352844	EML4-ALK	Lorlatinib	The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
33227290	EML4-ALK	Metformin	The effect of metformin in EML4-ALK+Â lung cancer alone and in combination with crizotinib in cell and rodent models.
36688904	EML4-ALK	Methylprednisolone	Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
36688904	EML4-ALK	Nedaplatin	Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
37934724	EML4-ALK	Nedaplatin	Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report.
25247338	EML4-ALK	Neratinib	NSCLC and HER2: between lights and shadows.
38433979	EML4-ALK	NVL-655	Overcoming Central Î²-Sheet #6 (CÎ²6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.
21504625	EML4-ALK	Olaparib	Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
32620470	EML4-ALK	Osimertinib	EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature.
36728908	EML4-ALK	Osimertinib	Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
38128381	EML4-ALK	Osimertinib	EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC.
32397295	EML4-ALK	Osimertinib	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
31372039	EML4-ALK	Osimertinib	Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.
29951342	EML4-ALK	Osimertinib	Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.
32622727	EML4-ALK	Osimertinib	Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
28528303	EML4-ALK	Osimertinib	Discovery of a potent dual ALK and EGFR T790M inhibitor.
35810049	EML4-ALK	Osimertinib	Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
34590027	EML4-ALK	Osimertinib	EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report.
33854939	EML4-ALK	Osimertinib	Successful management of a lung cancer patient harbouring both EGFR mutation and EML4-ALK fusion gene with disseminated intravascular coagulation.
33225619	EML4-ALK	Oteracil	Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway.
35656694	EML4-ALK	Paclitaxel	EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity.
37384219	EML4-ALK	Paclitaxel	Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report.
37934724	EML4-ALK	Paclitaxel	Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report.
30290287	EML4-ALK	Palbociclib	MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report.
29669761	EML4-ALK	Panobinostat	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.
22703830	EML4-ALK	Pazopanib	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
22787411	EML4-ALK	Pemetrexed	Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.
34034462	EML4-ALK	Pemetrexed	[A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors â€©and Chemotherapy].
24419060	EML4-ALK	Pemetrexed	The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
24001942	EML4-ALK	Pemetrexed	Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
36728908	EML4-ALK	Pemetrexed	Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
23265700	EML4-ALK	Pemetrexed	Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years.
26136951	EML4-ALK	Pemetrexed	Association between EML4-ALK fusion gene and thymidylate synthase mRNA expression in non-small cell lung cancer tissues.
25929953	EML4-ALK	Pemetrexed	Therapeutic management of ALK+ nonsmall cell lung cancer patients.
24940496	EML4-ALK	Pemetrexed	Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
36688904	EML4-ALK	Pemetrexed	Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
29951342	EML4-ALK	Pemetrexed	Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.
23559882	EML4-ALK	Pemetrexed	Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.
36207130	EML4-ALK	Pemetrexed	Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
24565582	EML4-ALK	Pemetrexed	Extending survival of stage IV non-small cell lung cancer.
22703830	EML4-ALK	Pemetrexed	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
21428883	EML4-ALK	Pemetrexed	Targeted therapies and other agents as first-line maintenance and beyond: particular benefit in pulmonary adenocarcinoma patients.
22056890	EML4-ALK	Pemetrexed	Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.
28781781	EML4-ALK	Pemetrexed	Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.
23918070	EML4-ALK	Pemetrexed	Second-Line Therapy for Advanced NSCLC.
33304133	EML4-ALK	Phenol	Identification of novel bioactive molecules from garlic bulbs: A special effort to determine the anticancer potential against lung cancer with targeted drugs.
32184963	EML4-ALK	Pictilisib	Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer.
34548910	EML4-ALK	Platinum	Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition.
38380327	EML4-ALK	Platinum	Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
34159737	EML4-ALK	Platinum	A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4â€‰years by switching to ceritinib.
28101031	EML4-ALK	Prednisolone	Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer.
31114237	EML4-ALK	Prednisone	Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer.
26130408	EML4-ALK	Pyrazole	Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
29091425	EML4-ALK	Quinoline	Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.
31370342	EML4-ALK	Resorcinol	Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.
26775573	EML4-ALK	Rociletinib	[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
30171175	EML4-ALK	Saracatinib	Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
36791109	EML4-ALK	Serine	ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression.
36750097	EML4-ALK	SNS-032	Piperlongumine conjugates induce targeted protein degradation.
26237499	EML4-ALK	Sorafenib	A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
22703830	EML4-ALK	Sorafenib	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
31118683	EML4-ALK	Sulbactam	Poor prognosis of pulmonary sarcomatoid carcinoma with KRAS mutation and ALK fusion.
22703830	EML4-ALK	Sunitinib	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
33225619	EML4-ALK	Tegafur	Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway.
35822498	EML4-ALK	Temozolomide	A new approach used in docking study for predicting the combination drug efficacy in EML4-ALK target of NSCLC.
25489176	EML4-ALK	Tivozanib	Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer.
29444468	EML4-ALK	Tocopherol	A major component of vitamin E, Î±-tocopherol inhibits the anti-tumor activity of crizotinib against cells transformed by EML4-ALK.
29444468	EML4-ALK	Tocotrienol	A major component of vitamin E, Î±-tocopherol inhibits the anti-tumor activity of crizotinib against cells transformed by EML4-ALK.
32245216	EML4-ALK	Trametinib	Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib.
29184034	EML4-ALK	Trametinib	MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
37149843	EML4-ALK	Tyrosine	EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
38195077	EML4-ALK	Tyrosine	Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
37384219	EML4-ALK	Tyrosine	Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report.
38433979	EML4-ALK	Tyrosine	Overcoming Central Î²-Sheet #6 (CÎ²6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.
37647220	EML4-ALK	Tyrosine	Synthesis and Preclinical Evaluation of [Methylpiperazine-11C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase.
38360931	EML4-ALK	Tyrosine	Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
37255276	EML4-ALK	Tyrosine	Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.
37434391	EML4-ALK	Tyrosine	Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
37448514	EML4-ALK	Tyrosine	Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports.
38407352	EML4-ALK	Tyrosine	Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
37637057	EML4-ALK	Tyrosine	Case Report: Response to ALK-TKIs in a metastatic lung cancer patient with morphological heterogeneity and consistent molecular features.
38380327	EML4-ALK	Tyrosine	Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
37686122	EML4-ALK	Tyrosine	A Functional Genomics Review of Non-Small-Cell Lung Cancer in Never Smokers.
38327793	EML4-ALK	Tyrosine	A small-molecule degrader selectively inhibits the growth of ALK-rearranged lung cancer with ceritinib resistance.
22703830	EML4-ALK	Vandetanib	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
27250896	EML4-ALK	Vandetanib	Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer.
22690483	EML4-ALK	Vemurafenib	[Will targeted therapies replace chemotherapy?].
29601554	EML4-ALK	Vinblastine	Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.
35159046	EML4-ALK	Vincristine	A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC.
24070465	EML4-ALK	Vinorelbine	Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents.
26361725	EML4-ALK	Zosuquidar	Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).

Statistics of # PMIDs per found drug for this fusion gene.

X-axis: drugs, Y-axis: # PMIDs

Fusion Gene and Diseases from the Found PubMed Abstracts

Diseases Related to This Fusion Gene from the Found PMID's MeSH terms

MeSH ID	MeSH Term
D002289	Carcinoma, Non-Small-Cell Lung; Lung Neoplasms
D008175	Carcinoma, Non-Small-Cell Lung; Lung Neoplasms
D000077192	Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Neoplasms, Muscle Tissue
D000077548	Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Neoplasms, Muscle Tissue
D009379	Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Neoplasms, Muscle Tissue
D019468	Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Disease Management Lung Neoplasms
D018450	Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Disease Management Lung Neoplasms
D001943	Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Lung Neoplasms; Carcinoma
D002277	Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Lung Neoplasms; Carcinoma
D002294	Carcinoma, Squamous Cell; Lung Neoplasms
D018572	Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Lung Neoplasms
D009369	Neoplasms
D004195	Anaplastic Lymphoma Kinase; Lung Neoplasms
D001932	Anaplastic Lymphoma Kinase; Brain Neoplasms
D010997	Anaplastic Lymphoma Kinase; Pleural Neoplasms
D008113	Lung Neoplasms; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms
D001859	Anaplastic Lymphoma Kinase; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Pleural Neoplasms
D017563	Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Anaplastic Lymphoma Kinase; Adenocarcinoma of Lung; Lung Diseases, Interstitial
D000077216	Anaplastic Lymphoma Kinase; Carcinoma, Ovarian Epithelial; Ovarian Neoplasms
D010051	Anaplastic Lymphoma Kinase; Carcinoma, Ovarian Epithelial; Ovarian Neoplasms
D000230	Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms
D009382	Anaplastic Lymphoma Kinase; Neoplasms, Unknown Primary
D013964	Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Thyroid Neoplasms
D000008	Abdominal Neoplasms; Brain Neoplasms; Lung Neoplasms
D009901	Adenocarcinoma; Adenocarcinoma of Lung; Brain Neoplasms Lung Neoplasms; Optic Nerve Diseases
D004067	Breast Neoplasms; Digestive System Neoplasms; Genital Neoplasms, Female; Hematologic Neoplasms; Lung Neoplasms; Neoplasms; Prostatic Neoplasms; Testicular Neoplasms; Thyroid Neoplasms
D005833	Breast Neoplasms; Digestive System Neoplasms; Genital Neoplasms, Female; Hematologic Neoplasms; Lung Neoplasms; Neoplasms; Prostatic Neoplasms; Testicular Neoplasms; Thyroid Neoplasms
D019337	Breast Neoplasms; Digestive System Neoplasms; Genital Neoplasms, Female; Hematologic Neoplasms; Lung Neoplasms; Neoplasms; Prostatic Neoplasms; Testicular Neoplasms; Thyroid Neoplasms
D011471	Breast Neoplasms; Digestive System Neoplasms; Genital Neoplasms, Female; Hematologic Neoplasms; Lung Neoplasms; Neoplasms; Prostatic Neoplasms; Testicular Neoplasms; Thyroid Neoplasms
D013736	Breast Neoplasms; Digestive System Neoplasms; Genital Neoplasms, Female; Hematologic Neoplasms; Lung Neoplasms; Neoplasms; Prostatic Neoplasms; Testicular Neoplasms; Thyroid Neoplasms
D052177	Kidney Diseases, Cystic; Lung Neoplasms; Adenocarcinoma of Lung
D000208	Acute Disease; Carcinoma, Non-Small-Cell Lung; Chronic Disease; Lung Diseases, Interstitial; Lung Neoplasms
D002908	Acute Disease; Carcinoma, Non-Small-Cell Lung; Chronic Disease; Lung Diseases, Interstitial; Lung Neoplasms
D018196	Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Pulmonary Disease, Chronic Obstructive
D029424	Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Pulmonary Disease, Chronic Obstructive
D019496	Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms
D018827	Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms
D017728	Lymphoma, Large-Cell, Anaplastic
D013120	Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Lung Neoplasms; Spinal Cord Neoplasms
D002830	Adenocarcinoma; Anaplastic Lymphoma Kinase; Choroid Neoplasms; Lung Neoplasms
D018287	Breast Neoplasms; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Lung Neoplasms; Skin Neoplasms
D018278	Breast Neoplasms; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Lung Neoplasms; Skin Neoplasms
D012878	Breast Neoplasms; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Lung Neoplasms; Skin Neoplasms

Fusion Gene and Diseases from Manual Curation and Other Resource

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene	Tgene	Disease	Source	PMID
EML4	ALK	Lung Adenocarcinoma	PubMed	33157918
EML4	ALK	Lung Adenocarcinoma	MyCancerGenome
EML4	ALK	Non-Small Cell Lung Carcinoma	MyCancerGenome
EML4	ALK	Adenocarcinoma Of Unknown Primary	MyCancerGenome
EML4	ALK	Unknown	MyCancerGenome
EML4	ALK	Breast Invasive Ductal Carcinoma	MyCancerGenome

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Hgene	EML4	C0007131	Non-Small Cell Lung Carcinoma	6	CTD_human
Hgene	EML4	C0027627	Neoplasm Metastasis	2	CTD_human
Hgene	EML4	C0152013	Adenocarcinoma of lung (disorder)	2	CTD_human
Tgene	ALK	C0007131	Non-Small Cell Lung Carcinoma	28	CGI;CTD_human
Tgene	ALK	C0027819	Neuroblastoma	13	CGI;CTD_human;ORPHANET
Tgene	ALK	C0152013	Adenocarcinoma of lung (disorder)	8	CGI;CTD_human
Tgene	ALK	C2751681	NEUROBLASTOMA, SUSCEPTIBILITY TO, 3	8	CLINGEN;UNIPROT
Tgene	ALK	C0206180	Ki-1+ Anaplastic Large Cell Lymphoma	6	CGI;CTD_human
Tgene	ALK	C0334121	Inflammatory Myofibroblastic Tumor	4	CGI;CTD_human;ORPHANET
Tgene	ALK	C0018199	Granuloma, Plasma Cell	3	CTD_human
Tgene	ALK	C0007621	Neoplastic Cell Transformation	2	CTD_human
Tgene	ALK	C0027627	Neoplasm Metastasis	2	CTD_human
Tgene	ALK	C0238463	Papillary thyroid carcinoma	2	ORPHANET

Details of the Found Drugs/Small Molecules

Details of the Found Drugs/Small Molecules from DrugBank.

DrugBank ID	Generic Name	Drug Type	Drug Group	Structure	Weight	Chemical Formula	Synonyms	SMILES
DB08865	Crizotinib	small molecule	"approved, investigational"		450.337	C21H22Cl2FN5O	"(R)-crizotinib, Crizotinib, Crizotinibum"	C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
DB08916	Afatinib	small molecule	approved		485.938	C24H25ClFN5O3	"Afatinib, Afatinibum"	CN(C)CC=CC(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1
DB11363	Alectinib	small molecule	"approved, investigational"		482.6166	C30H34N4O2	"9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile, Alectinib"	CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O
DB06626	Axitinib	small molecule	"approved, investigational"		386.47	C22H18N4OS	"Axitinib, Axitinibum, N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide"	CNC(=O)C1=C(SC2=CC=C3C(NN=C3C=CC3=CC=CC=N3)=C2)C=CC=C1
DB00993	Azathioprine	small molecule	approved		277.263	C9H7N7O2S	"6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine, 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine, Azamun, Azathioprine, Azathioprinum, Azatioprina"	CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O
DB12267	Brigatinib	small molecule	"approved, investigational"		584.1	C29H39ClN7O2P	Brigatinib	COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1
DB01101	Capecitabine	small molecule	"approved, investigational"		359.3501	C15H22FN3O6	"(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester, Capecitabin, Capecitabina, Capecitabine, Capécitabine, Capecitabinum, Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
DB00958	Carboplatin	small molecule	approved		371.254	C6H12N2O4Pt	"Carboplatin, Carboplatine, Carboplatino, CBDCA, cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II), cis-diammine(1,1-cyclobutanedicarboxylato)platinum, cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)"	[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
DB01329	Cefoperazone	small molecule	"approved, investigational"		645.67	C25H27N9O8S2	"(6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure, (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)C1=CC=C(O)C=C1)C(O)=O
DB09063	Ceritinib	small molecule	approved		558.135	C28H36ClN5O3S	"Ceritinib, Céritinib, Ceritinibum, N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide"	CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1
DB00439	Cerivastatin	small molecule	"approved, withdrawn"		459.5503	C26H34FNO5	Cerivastatin	COCC1=C(C2=CC=C(F)C=C2)C(C=C[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C
DB00148	Creatine	small molecule	"approved, investigational, nutraceutical"		131.1332	C4H9N3O2	"((amino(Imino)methyl)(methyl)amino)acetic acid, (alpha-Methylguanido)acetic acid, (N-methylcarbamimidamido)acetic acid, (α-methylguanido)acetic acid, alpha-Methylguanidino acetic acid, Creatin, Creatine, Kreatin, Methylglycocyamine, N-(aminoiminomethyl)	CN(CC(O)=O)C(N)=N
DB08912	Dabrafenib	small molecule	"approved, investigational"		519.562	C23H20F3N5O2S2	Dabrafenib	CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
DB00851	Dacarbazine	small molecule	"approved, investigational"		182.187	C6H10N6O	"4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide, 4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide, 4-(dimethyltriazeno)imidazole-5-carboxamide, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 5-(3,3-dimethyltriazeno)imidazole-4-carboxamid	CN(C)N=NC1=C(N=CN1)C(N)=O
DB01254	Dasatinib	small molecule	"approved, investigational"		488.006	C22H26ClN7O2S	"Anh. dasatinib, Anhydrous dasatinib, BMS dasatinib, Dasatinib, Dasatinib (anh.), dasatinib (anhydrous), Dasatinib anhydrous, Dasatinibum, N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-ca	CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
DB01248	Docetaxel	small molecule	"approved, investigational"		807.8792	C43H53NO14	"Docetaxel, Docetaxel anhydrous, N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel, N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol, TXL"	[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
DB11986	Entrectinib	small molecule	"approved, investigational"		560.65	C31H34F2N6O2	"Entrectinib, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide"	CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)C(NC2CCOCC2)=C1
DB00530	Erlotinib	small molecule	"approved, investigational"		393.4357	C22H23N3O4	"[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine, Erlotinib"	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
DB00773	Etoposide	small molecule	approved		588.5566	C29H32O13	"(−)-etoposide, 4-demethylepipodophyllotoxin β-D-ethylideneglucoside, 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside), 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)	[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O
DB00317	Gefitinib	small molecule	"approved, investigational"		446.902	C22H24ClFN4O3	"4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, Gefitinib, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine"	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
DB00441	Gemcitabine	small molecule	approved		263.1981	C9H11F2N3O4	"2'-Deoxy-2',2'-difluorocytidine, 2',2'-Difluorodeoxycytidine, 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, Gemcitabin, Gemcitabina, Gemcitabine, Gemcitabinum"	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
DB12141	Gilteritinib	small molecule	"approved, investigational"		552.724	C29H44N8O3	Gilteritinib	CCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O
DB09257	Gimeracil	small molecule	approved		145.54	C5H4ClNO2	"5-Chloro-2,4-dihydroxypyridine, 5-Chloro-4-hydroxy-2-pyridone, Gimeracil, gimestat, Teysuno, Ts-1 (TN)"	OC1=CC(=O)NC=C1Cl
DB00619	Imatinib	small molecule	approved		493.6027	C29H31N7O	"Imatinib, Imatinibum, α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide"	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
DB00483	Gallamine triethiodide	small molecule	approved		891.5291	C30H60I3N3O3	"Gallamin triethiodid, Gallamine triethiodide, Gallamini Triethiodidum, Triéthiodure de Gallamine, Trietioduro de galamina"	[I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC
DB05382	Iodine	small molecule	"approved, investigational"		253.8089	I2	"diiodine, I2, Iodine, iodo, Jod, molecular iodine"	II
DB01259	Lapatinib	small molecule	"approved, investigational"		581.058	C29H26ClFN4O4S	"Lapatinib, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine"	CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1
DB09078	Lenvatinib	small molecule	"approved, investigational"		426.86	C21H19ClN4O4	"4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, Lenvatinib"	COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O
DB01006	Letrozole	small molecule	"approved, investigational"		285.3027	C17H11N5	"Letrozol, Letrozole"	N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
DB12130	Lorlatinib	small molecule	"approved, investigational"		406.421	C21H19FN6O2	Lorlatinib	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2
DB00331	Metformin	small molecule	approved		129.1636	C4H11N5	"1,1-Dimethylbiguanide, Dimethylbiguanid, Metformin, Metformina, Metformine, Metforminum"	CN(C)C(=N)NC(N)=N
DB00959	Methylprednisolone	small molecule	"approved, vet_approved"		374.4706	C22H30O5	"(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione, 1-dehydro-6α-methylhydrocortisone, 6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione, delta(1)-6alpha-Methylhydrocortisone, Methylprednisolon, Methylprednisolone, Methylprednisol	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
DB13145	Nedaplatin	small molecule	"approved, investigational"		303.181	C2H8N2O3Pt	"(glycolato-O,O')diammineplatinum(II), CDGP, cis-Diammine (glycolato)platinum, cis-diammine(glycolato)platinum, cis-Diammine(glycolato)platinum(II), Nedaplatin"	[H][N]([H])([H])[Pt]1(OCC(=O)O1)[N]([H])([H])[H]
DB11828	Neratinib	small molecule	"approved, investigational"		557.05	C30H29ClN6O3	Neratinib	CCOC1=C(NC(=O)C=CCN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N
DB09074	Olaparib	small molecule	approved		434.4628	C24H23FN4O3	"4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one, Olaparib"	FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
DB09330	Osimertinib	small molecule	approved		499.619	C28H33N7O2	"Mereletinib, N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide, Osimertinib, Osimertinibum"	COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
DB03209	Oteracil	small molecule	approved		157.0843	C4H3N3O4	"5-azaorotic acid, Allantoxanic acid, Oteracil, Oxonate, Oxonic Acid"	OC(=O)C1=NC(=O)NC(=O)N1
DB01229	Paclitaxel	small molecule	"approved, vet_approved"		853.9061	C47H51NO14	"5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine, ABI-007 COMPONENT PACLITAXEL, BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
DB09073	Palbociclib	small molecule	"approved, investigational"		447.5328	C24H29N7O2	"6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, Palbociclib"	CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O
DB06603	Panobinostat	small molecule	"approved, investigational"		349.434	C21H23N3O2	"(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-, hydroxypropyl-B-cyclodextrin-panobinostat complex, Panobinostat, Panobin	CC1=C(CCNCC2=CC=C(C=CC(=O)NO)C=C2)C2=CC=CC=C2N1
DB06589	Pazopanib	small molecule	approved		437.518	C21H23N7O2S	"Pazopanib, Pazopanibum"	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
DB00642	Pemetrexed	small molecule	"approved, investigational"		427.4106	C20H21N5O6	Pemetrexed	NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1
DB14083	Bisphenol A diglycidyl ether	small molecule	"approved, experimental"		340.4129	C21H24O4	"2,2-Bis(4-glycidyloxyphenyl)propane, 2,2-bis(4'-glycidyloxyphenyl)propane, 4,4'-isopropylidenediphenol diglycidyl ether, Bisphenol diglycidyl ether, DGEBPA, Diglycidyl bisphenol A ether"	CC(C)(C1=CC=C(OCC2CO2)C=C1)C1=CC=C(OCC2CO2)C=C1
DB09378	Fluprednisolone	small molecule	approved		378.44	C21H27FO5	"6alpha-Fluoroprednisolone, Fluprednisolone, Fluprednisolonum"	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
DB09383	Meprednisone	small molecule	"approved, investigational"		372.461	C22H28O5	Meprednisone	[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3([H])C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO
DB09115	Diiodohydroxyquinoline	small molecule	approved		396.954	C9H5I2NO	"Diiodohydroxyquin, Diiodohydroxyquinoline, Iodoquinol, Ioquin"	OC1=C2N=CC=CC2=C(I)C=C1I
DB11254	Hexylresorcinol	small molecule	approved		194.2701	C12H18O2	"4-hexyl-1,3-benzenediol, 4-hexylresorcinol, Hexylresorcinol"	CCCCCCC1=C(O)C=C(O)C=C1
DB14096	"1,2-icosapentoyl-sn-glycero-3-phosphoserine"	small molecule	"approved, experimental"		842.064	C47H72NO10P		[H]C(N)(COP(O)(=O)OCC([H])(COC(=O)CCCC=C/CC=C/CC=C/CC=C/CC=C/CC)OC(=O)CCCCC=C/CC=C/CC=C/CC=C/CC=C/CC)C(O)=O
DB00398	Sorafenib	small molecule	"approved, investigational"		464.825	C21H16ClF3N4O3	"4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide, N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, Sorafénib, Sorafenib, Sorafenibum"	CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
DB09324	Sulbactam	small molecule	approved		233.242	C8H11NO5S	"(2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide, (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide, Penicillanic acid 1,1-dioxide, Penicillanic acid sulfone, Sulbactam, S	[H][C@@]12CC(=O)N1[C@@]([H])(C(O)=O)C(C)(C)S2(=O)=O
DB01268	Sunitinib	small molecule	"approved, investigational"		398.4738	C22H27FN4O2	"Sunitinib, Sunitinibum"	CCN(CC)CCNC(=O)C1=C(C)NC(C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
DB09256	Tegafur	small molecule	"approved, investigational"		200.169	C8H9FN2O3	"1-(2-Tetrahydrofuryl)-5-fluorouracil, Tegafur"	FC1=CN(C2CCCO2)C(=O)NC1=O
DB00853	Temozolomide	small molecule	"approved, investigational"		194.1508	C6H6N6O2	"(S)-perillyl alcohol temozolomide, 3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide, 8-	CN1N=NC2=C(N=CN2C1=O)C(N)=O
DB11800	Tivozanib	small molecule	"approved, investigational"		454.863	C22H19ClN4O5	Tivozanib	COC1=C(OC)C=C2C(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=CC=NC2=C1
DB14003	alpha-Tocopherol acetate	small molecule	approved				"Tocopherol acetate, Tocopherol acetate, unspecified, Tocopheryl acetate, Vitamin E (alpha tocopherol acetate), Vitamin E acetate, Vitamin E acetate, unspecified form"
DB08911	Trametinib	small molecule	approved		615.3948	C26H23FIN5O4	"Tramétinib, Trametinib, Trametinibum"	CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1
DB00765	Metyrosine	small molecule	approved		195.2151	C10H13NO3	"(-)-alpha-Methyl-L-tyrosine, (–)-α-methyl-L-tyrosine, (S)-alpha-Methyltyrosine, Methyltyrosine, Metirosin, Metirosina, Métirosine, Metirosine, Metirosinum, Metyrosine, α-methyl-L-p-tyrosine, α-methyl-p-tyrosine, α-methyl-para-tyrosine, α-MPT"	C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O
DB05294	Vandetanib	small molecule	approved		475.354	C22H24BrFN4O2	"N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, Vandetanib"	COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
DB08881	Vemurafenib	small molecule	approved		489.922	C23H18ClF2N3O3S	"Vémurafénib, Vemurafenib, Vemurafenibum"	CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
DB00570	Vinblastine	small molecule	approved		810.9741	C46H58N4O9	"Vinblastin, Vinblastina, Vinblastine, Vinblastinum, Vincaleukoblastine"	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC
DB00541	Vincristine	small molecule	"approved, investigational"		824.972	C46H56N4O10	"22-Oxovincaleukoblastin, 22-Oxovincaleukoblastine, Leurocristine, Vincristin, Vincristina, Vincristine, Vincristinum"	[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@H]5C[N@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC
DB00361	Vinorelbine	small molecule	"approved, investigational"		778.947	C45H54N4O8	"5'-Noranhydrovinblastine, Vinorelbin, Vinorelbina, Vinorelbine, Vinorelbinum"	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC

ADME (absorption, distribution, metabolism, and excretion) Properties of the Found Drugs/Small Molecules Using the Qikprop of Schrödinger.

Molecule	# stars	# amines	# amidines	# acids	# amides	# rotors	# rtvFG	CNS	mol_MW	dipole	SASA	FOSA	FISA	PISA	WPSA	volume	donorHB	accptHB	dip^2/V	ACxDN^.5/SA	glob	QPpolrz	QPlogPC16	QPlogPoct	QPlogPw	QPlogPo/w	QPlogS	CIQPlogS	QPlogHERG	QPPCaco	QPlogBB	QPPMDCK	QPlogKp	IP(eV)	EA(eV)	# metab	QPlogKhsa	Human Oral Absorption	Percent Human Oral Absorption	SAfluorine	SAamideO	PSA	# NandO	Rule Of Five	# ringatoms	# in 34	# in 56	# noncon	# nonHatm	Rule Of Three	Jm	Spermine
Crizotinib	1	1	0	0	0	4	0	0	450.342	1.836	705.819	276.242	115.308	196.547	117.722	1279.647	3	5.25	0.002635	0.0128833	0.8076044	44.366	13.291	22.352	12.263	4.113	-5.569	-6.085	-6.309	199.22	-0.169	422.446	-4.631	7.898	0.573	5	0.763	3	92.18	40.557	0	73.496	6	0	23	0	23	5	30	0	0
Afatinib	0	1	0	0	0	8	1	1	485.945	2.367	801.858	385.311	99.31	210.914	106.322	1459.409	2	9.45	0.0038401	0.0166667	0.7759837	49.129	14.767	24.514	14.269	3.792	-5.269	-5.224	-6.889	282.513	-0.359	533.702	-3.901	8.461	1.288	4	0.34	3	93.017	41.311	0	94.953	8	0	21	0	21	4	34	0	0
Alectinib	1	1	0	0	0	2	0	1	482.624	10.09	805.781	513.34	122.803	169.638	0	1516.661	1	8.2	0.0671295	0.0101765	0.7922711	54.879	14.651	25.093	12.748	4.17	-7.264	-6.772	-6.428	169.145	-0.463	80.18	-5.056	8.763	0.83	2	0.999	1	91.241	0	0	80.344	6	0	29	0	29	10	36	1	0
Alvocidib	0	1	0	0	0	3	0	1	401.846	2.793	643.039	192.466	160.188	233.269	57.115	1167.714	2	6.7	0.0066807	0.0147351	0.8339734	40.879	12.695	20.601	12.83	2.56	-4.105	-4.612	-6.057	74.771	-0.614	68.194	-5.425	9.062	0.696	5	0.358	3	75.469	0	0	96.933	6	0	22	0	22	5	28	0	0
Anlotinib	0	1	0	0	0	7	0	0	407.443	8.666	733.95	334.484	99.849	262.726	36.892	1288.911	3	4	0.0582607	0.0094396	0.7803939	43.443	13.297	21.526	10.754	4.505	-5.572	-5.566	-7.065	279.213	-0.462	219.505	-3.825	8.586	0.83	4	0.847	3	100	36.892	0	72.21	6	0	22	3	19	3	30	0	0
ATP	7	0	0	4	0	14	3	-2	507.183	16.782	651.799	79.316	474.446	86.578	11.458	1184.379	4	20.1	0.2377977	0.0616755	0.8305745	33.082	14.164	31.901	27.676	-2.306	-0.374	-2.222	2.544	0.005	-4.837	0.001	-8.614	8.012	0.328	4	-2.623	1	0	0	0	280.557	18	3	14	0	14	4	31	1	0.001
AUY922	0	1	0	0	0	7	0	-1	479.575	4.619	756.852	458.915	152.785	145.151	0	1463.688	3	9.2	0.0145742	0.0210541	0.8237329	49.314	14.532	25.942	15.479	2.984	-4.283	-5.259	-5.803	87.889	-0.961	39.514	-5.215	8.915	0.689	5	0.468	3	79.208	0	0	111.869	8	0	23	0	23	4	35	0	0
Axitinib	0	0	0	0	0	6	0	-1	386.47	6.703	686.86	106.958	113.752	435.441	30.709	1211.753	2	4.5	0.037077	0.0092653	0.8002756	42.646	14.044	20.192	11.157	4.66	-6.157	-6.444	-6.84	826.394	-0.907	593.013	-1.506	8.542	0.891	1	0.709	3	100	0	0	75.407	5	0	21	0	21	0	28	1	0.008
Azathioprine	0	0	0	0	0	3	0	-2	277.26	11.386	474.148	72.687	202.808	175.997	22.656	789.127	1	6	0.1642783	0.0126543	0.8709955	25.181	8.575	15.402	10.157	0.672	-2.534	-3.342	-4.459	118.215	-1.344	65.482	-4.349	9.45	1.425	1	-0.459	3	67.975	0	0	112.181	9	0	14	0	14	0	19	0	0.036
Brigatinib	3	2	0	0	0	6	0	1	584.1	5.238	961.607	565.227	67.713	277.28	51.387	1788.438	1	12.75	0.0153438	0.0132591	0.7409974	64.215	18.313	29.943	17.098	4.04	-5.496	-5.012	-8.498	140.467	0.303	138.751	-5.34	7.779	0.313	5	0.535	3	76.079	0	0	80.704	9	1	30	0	30	9	40	0	0
Capecitabine	0	0	0	0	0	7	0	-2	359.354	3.753	639.132	365.575	201.409	39.215	32.933	1117.697	3	11.1	0.0126014	0.030081	0.8149363	34.456	10.748	21.81	16.689	0.397	-3.323	-2.651	-4.714	121.881	-1.799	77.048	-4.421	9.476	0.914	3	-0.653	3	66.602	32.933	0	138.865	9	0	11	0	11	4	25	0	0.006
Cefoperazone	6	0	0	1	2	10	3	-2	645.664	19.997	943.016	373.322	377.62	130.514	61.56	1769.415	2.25	15.5	0.2259864	0.0246549	0.7502382	59.483	19.532	35.745	24.747	0.748	-4.865	-5.668	-1.64	0.319	-4.361	0.498	-7.059	9.314	1.251	4	-0.967	1	0	0	39.504	272.829	17	2	25	4	21	5	44	1	0
Ceritinib	2	1	0	0	0	8	0	1	558.137	7.861	925.008	539.973	106.508	229.983	48.543	1716.653	2	8.25	0.0359981	0.0126131	0.7495625	59.606	17.702	27.699	13.542	5.627	-7.574	-7.267	-7.407	241.425	-0.665	217.275	-3.967	8.207	0.734	5	1.232	1	76.622	0	0	94.504	8	2	24	0	24	5	38	1	0
Cerivastatin	0	0	0	1	0	13	0	-2	459.557	4.52	735.349	467.18	140.911	98.588	28.671	1451.48	2	7.1	0.0140739	0.0136546	0.8430991	44.528	13.55	21.56	10.183	5.078	-5.005	-6.382	-2.733	115.676	-1.471	87.766	-2.521	9.495	0.444	7	0.442	2	80.648	28.671	0	105.415	6	1	12	0	12	0	33	1	0.014
Creatine	2	0	1	1	0	3	0	-2	131.134	5.748	317.877	105.072	212.805	0	0	479.986	4	4	0.068843	0.0251669	0.932662	11.129	5.194	12.217	11.068	-0.562	-0.531	-0.675	-0.814	24.069	-1.248	11.203	-7.216	8.415	-0.442	2	-0.995	2	48.381	0	0	107.226	5	0	0	0	0	0	9	0	0.002
Dabrafenib	1	0	0	0	0	5	0	-2	519.559	6.349	795.401	196.18	155.186	330.478	113.556	1439.05	3	8.5	0.0280098	0.0185095	0.7749906	51.382	15.436	27.171	16.64	4.212	-7.166	-7.62	-6.749	334.4	-1.182	634.161	-2.735	8.781	1.417	3	0.558	1	83.826	90.183	0	103.886	7	1	23	0	23	0	35	1	0
Dacarbazine	0	0	0	0	0	3	1	-2	182.185	6.126	413.746	167.68	175.18	70.886	0	643.846	2	7	0.0582937	0.0239265	0.8715372	18.363	6.183	13.122	11.551	-0.581	-1.493	-0.916	-3.949	216.106	-1.155	94.45	-4.21	9.196	1.13	3	-0.844	3	65.328	0	0	107.53	7	0	5	0	5	0	13	0	0.361
Dasatinib	0	1	0	0	0	7	0	-1	488.006	2.557	834.038	388.665	128.085	221.544	95.744	1474.925	3	10.7	0.0044341	0.0222208	0.751322	50.494	16.079	27.143	17.527	3.004	-5.494	-4.859	-7.339	150.721	-0.738	236.82	-4.49	8.657	1.396	6	0.15	3	83.519	0	0	105.843	9	0	23	0	23	4	33	0	0
Dinaciclib	0	0	0	0	0	7	0	-1	396.491	7.758	658.34	374.342	119.507	164.491	0	1240.69	2	5.7	0.0485146	0.0122445	0.8481845	40.575	12.195	19.878	10.235	3.922	-4.989	-5.871	-4.773	728.815	-0.966	351.444	-2.47	8.178	0.907	4	0.559	3	100	0	0	87.005	8	0	21	0	21	5	29	0	0.014
Docetaxel	7	0	0	0	0	13	3	-2	807.89	4.675	1031.915	496.508	220.255	315.153	0	2179.541	4	17.35	0.0100289	0.0336268	0.7878273	75.734	22.7	41.572	25.925	4.202	-6.326	-8.889	-6.468	80.765	-2.586	32.598	-3.22	9.525	0.515	8	0.472	1	59.766	0	0	223.683	15	2	29	4	22	13	58	2	0
Ensartinib	1	1	0	0	0	7	0	-2	561.442	12.666	835.965	331.46	193.274	204.907	106.324	1558.094	4	10.25	0.1029655	0.0245226	0.7775102	53.663	16.916	31.334	18.887	3.137	-5.641	-6.445	-6.835	36.306	-1.33	58.102	-5.75	8.863	1.121	3	0.426	2	60.278	28.155	0	135.079	9	1	24	0	24	4	38	0	0
Entrectinib	1	1	0	0	0	6	0	1	560.645	4.959	918.941	435.368	108.96	280.83	93.783	1702.611	2	8.2	0.0144407	0.0126195	0.7503916	60.814	16.99	28.185	14.298	5.775	-8.008	-7.618	-7.636	228.841	-0.46	362.83	-4.025	8.177	0.525	5	1.29	1	77.074	93.783	0	93.206	8	2	33	0	33	9	41	1	0
Erlotinib	0	0	0	0	0	11	0	0	393.441	5.635	758.119	388.558	35.855	333.706	0	1316.839	1.5	7.4	0.024109	0.0119547	0.7663898	42.67	13.578	19.862	11.117	4.505	-5.511	-5.211	-6.903	4527.765	-0.506	2530.946	0.051	8.224	1.023	6	0.236	3	100	0	0	63.303	7	0	16	0	16	0	29	0	1.366
Etoposide	0	0	0	0	0	7	4	-2	588.564	7.765	794.827	528.495	176.264	90.068	0	1551.252	3	16.95	0.038865	0.0369367	0.815356	52.293	15.106	31.529	22.989	0.607	-3.752	-5.392	-4.949	211.051	-1.626	92.065	-3.779	8.702	0.301	8	-0.662	2	46.183	0	0	168.483	13	2	32	0	32	13	42	1	0.017
Fructose-6-phosphate	4	0	0	2	0	13	2	-2	260.137	4.701	458.481	99.828	355.085	0	3.568	747.185	5	12.8	0.0295751	0.0624271	0.8685514	15.401	8.735	19.646	20.302	-2.207	-0.335	-0.33	-0.044	0.273	-3.349	0.118	-6.816	10.366	-0.123	4	-1.727	1	0	0	0	181.771	9	1	0	0	0	0	16	1	0.018
Ganetespib	0	0	0	0	0	3	0	-2	364.403	7.011	587.495	199.143	196.238	192.114	0	1097.012	3	4.5	0.044801	0.0132669	0.8755914	37.657	11.908	20.213	11.939	2.816	-4.627	-5.83	-4.461	136.451	-1.324	57.46	-4.171	8.403	0.197	3	0.492	3	81.646	0	0	104.623	7	0	20	0	20	0	27	0	0.001
Gefitinib	0	1	0	0	0	8	0	1	446.908	6.89	731.552	355.68	36.204	229.873	109.795	1326.688	1	7.7	0.0357852	0.0105256	0.7981774	43.999	12.913	20.554	10.612	4.278	-4.656	-5.22	-6.62	1120.664	0.37	2472.647	-2.671	8.452	1.244	5	0.342	3	100	41.303	0	60.269	7	0	22	0	22	4	31	0	0.021
Geldanamycin	3	0	0	0	0	19	1	-2	560.643	9.884	838.809	552.691	238.711	47.407	0	1679.276	3.25	14.1	0.0581705	0.0303038	0.8145479	49.303	16.403	29.469	18.141	2.157	-3.361	-5.242	-4.759	53.976	-2.98	21.087	-3.928	9.45	1.866	11	-0.372	1	44.661	0	0	187.824	11	2	6	0	6	0	40	1	0.029
Gemcitabine	0	0	0	0	0	4	0	-2	263.2	10.531	417.6	98.755	203.663	59.573	55.61	710.142	4	9.1	0.15617	0.0435824	0.9217962	20.266	7.504	19.662	16.474	-1.131	-1.707	-1.714	-3.082	116.029	-1.139	97.25	-4.679	9.17	0.117	3	-0.773	2	57.276	55.61	0	114.625	7	0	11	0	11	4	18	0	0.108
Gilteritinib	0	2	0	0	0	7	0	0	552.718	5.544	887.969	661.213	121.054	105.703	0	1725.23	3	11.95	0.0178178	0.0233094	0.7834267	59.404	16.552	30.696	18.019	3.097	-4.334	-4.364	-6.993	43.828	-0.376	20.606	-6.831	8.102	0.464	5	0.589	2	48.547	0	0	113.438	11	2	30	0	30	14	40	0	0
Gimeracil	2	0	0	0	0	1	0	-1	145.545	2.357	302.942	0	139.364	93.582	69.996	449.392	2	3.25	0.012357	0.0151719	0.936603	12.082	5.075	8.673	7.967	-0.116	-0.776	-1.379	-3.004	472.403	-0.384	531.811	-3.662	9.039	0.42	2	-0.701	2	74.13	0	0	64.938	3	0	6	0	6	0	9	0	2.448
Hematoxylin	0	0	0	0	0	5	0	-2	302.283	1.168	498.538	98.586	243.26	156.692	0	861.269	5	4.5	0.0015841	0.0201836	0.8781303	26.6	10.236	18.7	14.292	0.618	-2.504	-3.951	-4.251	48.872	-1.841	18.94	-4.971	8.797	-0.048	7	-0.347	2	60.796	0	0	116.846	6	0	17	0	17	4	22	1	0.01
Imatinib	0	2	0	0	0	7	0	1	493.61	7.42	872.541	332.379	107.824	432.337	0	1599.868	2	10.5	0.0344172	0.0170184	0.7581738	57.507	17.636	28.292	17.221	3.48	-4.573	-4.454	-8.959	58.506	-0.312	28.158	-5.437	8.408	1.031	8	0.525	2	78.953	0	0	89.982	8	0	30	0	30	4	37	1	0
Lapatinib	4	1	0	0	0	10	0	-2	581.06	7.964	985.778	219.657	136.018	521.691	108.412	1740.967	1	8.25	0.0364333	0.008369	0.7099805	62.081	20.276	27.718	13.988	6.263	-8.638	-8.299	-9.439	126.748	-1.174	230.409	-3.291	8.361	1.326	6	1.219	1	75.338	46.884	0	98.446	8	2	27	0	27	0	40	1	0
Lenvatinib	0	0	0	0	1	6	0	-2	426.858	10.096	740.358	255.678	187.819	231.169	65.693	1282.184	4	6.75	0.0795002	0.0182344	0.7709448	43.514	14.597	25.296	17.265	2.578	-5.475	-5.083	-4.966	107.427	-1.744	160.518	-3.591	8.846	1.242	3	0.01	3	78.393	0	23.078	124.857	8	0	19	3	16	3	30	0	0
Letrozole	0	0	0	0	0	5	0	-2	285.307	4.602	557.581	3.733	186.515	367.333	0	954.242	0	6	0.0221942	0	0.8406776	32.332	10.933	14.496	9.635	1.554	-3.828	-4.368	-5.862	168.724	-1.497	72.28	-3.183	10.37	1.144	1	-0.429	3	75.906	0	0	79.013	5	0	17	0	17	0	22	0	0.028
Lorlatinib	0	0	0	0	0	2	0	-2	406.418	3.336	628.512	252.012	177.909	151.734	46.857	1166.832	2	7.75	0.0095375	0.0174383	0.8528193	40.707	11.548	21.155	13.612	2.432	-5.888	-6.248	-4.637	203.607	-1.073	159.926	-4.072	8.301	0.708	4	0.234	3	82.509	46.857	0	110.044	8	0	22	0	17	2	30	1	0
Metformin	2	0	1	0	0	4	0	-2	129.164	6.581	333.82	152.711	176.87	4.238	0	509.136	5	3.5	0.0850575	0.0234445	0.923724	11.694	5.424	13.6	11.643	-0.766	-0.395	-0.649	-2.786	208.275	-1.06	90.757	-6.443	8.254	-0.587	2	-0.917	2	63.957	0	0	95.356	5	0	0	0	0	0	9	0	0.019
Methylprednisolone	0	0	0	0	0	5	0	-2	374.476	1.373	602.416	339.131	194.238	69.047	0	1137.971	3	8.15	0.0016563	0.0234327	0.8750288	36.836	11.394	21.043	14.278	1.788	-3.491	-3.794	-3.883	142.541	-1.429	60.236	-4.376	10.367	0.841	4	-0.009	3	75.964	0	0	109.496	5	0	17	0	17	12	27	0	0.003
Neratinib	3	1	0	0	0	12	1	-2	557.05	10.881	987.473	392.771	147.499	388.59	58.613	1767.473	2	10	0.0669913	0.0143215	0.7159373	60.586	20.092	29.588	15.895	5.122	-8.405	-7.746	-8.708	98.643	-1.536	93.759	-3.78	8.28	1.245	8	0.816	1	66.711	0	0	114.552	9	2	22	0	22	0	40	2	0
Olaparib	0	0	0	0	1	4	1	-1	434.469	9.279	693.521	267.43	131.804	256.608	37.68	1298.333	1	8	0.066316	0.0115353	0.8299074	45.687	12.987	22.148	14.304	2.988	-4.631	-5.059	-4.134	356.927	-0.861	422.886	-2.661	9.375	1.132	1	0.071	3	90.125	37.68	24.3	109.126	7	0	25	3	22	7	32	0	0.022
Osimertinib	1	1	0	0	0	9	1	1	499.614	8.402	879.493	453.769	91.086	334.638	0	1624.519	2	8.75	0.0434592	0.0140699	0.7598874	56.276	17.04	26.751	14.294	4.891	-6.221	-6.031	-7.739	338.091	-0.632	169.5	-3.218	7.827	0.328	5	0.852	1	100	0	0	82.39	9	0	21	0	21	0	37	1	0
Oteracil	6	0	0	1	0	1	0	-2	157.085	7.792	294.182	0	287.499	6.683	0	444.003	2.25	5.75	0.136757	0.0293186	0.9567668	11.037	5.252	12.005	11.166	-1.019	-1.545	-0.985	-0.456	4.711	-1.591	1.922	-6.699	10.881	1.615	0	-0.979	2	33.027	0	0	149.175	7	0	6	0	6	0	11	1	0.007
Paclitaxel	9	0	0	0	0	13	4	-2	853.918	3.085	1106.647	390.621	215.373	500.653	0	2349.483	3	17.65	0.0040507	0.0276246	0.7723323	84.306	25.334	43.472	26.164	5.449	-7.387	-10.117	-7.604	89.85	-2.627	36.579	-2.477	9.611	0.808	8	0.809	1	54.939	0	0	236.456	15	3	35	4	28	13	62	2	0
Palbociclib	0	1	0	0	0	3	0	1	447.539	8.879	759.602	473.39	136.918	149.294	0	1400.088	2	11	0.0563052	0.0204796	0.7967996	49.377	13.752	25.965	16.596	2.081	-4.388	-3.903	-6.258	124.282	-0.657	57.464	-5.292	8.18	1.138	3	0.131	3	76.617	0	0	109.79	9	0	27	0	27	9	33	0	0
Panobinostat	0	1	0	0	0	9	2	-2	349.432	7.087	695.496	201.185	162.381	331.93	0	1202.472	4	5.7	0.041769	0.0163912	0.7862978	39.36	13.834	22.419	14.243	2.629	-3.76	-3.677	-7.299	71.275	-1.331	31.506	-4.541	8.068	0.721	4	0.173	3	75.506	0	0	93.177	5	0	15	0	15	0	26	0	0.002
Pazopanib	0	0	0	0	0	6	0	-2	437.518	5.767	676.507	277.492	144.622	253.58	0.812	1261.138	3	8.5	0.026368	0.0217624	0.8344518	42.886	13.419	23.61	15.499	2.748	-4.584	-5.888	-5.42	421.164	-1.181	196.28	-2.716	8.198	0.673	5	0.14	3	90.009	0	0	106.756	9	0	21	0	21	0	31	0	0.022
Pemetrexed	4	0	0	2	0	10	0	-2	427.416	5.481	713.585	139.697	417.335	156.553	0	1273.701	6.25	9.75	0.0235826	0.0341585	0.7963378	39.894	15.567	28.826	21.892	0.824	-3.911	-4.638	-1.959	0.07	-4.427	0.026	-7.699	8.333	0.179	4	-0.713	1	0	0	0	227.304	11	2	15	0	15	0	31	1	0
Phenol	6	0	0	0	0	1	0	1	94.113	1.53	277.38	0	54.599	222.78	0	401.016	1	0.75	0.005838	0.0027039	0.9481238	11.38	4.25	4.998	4.256	1.459	-0.05	-1.073	-3.434	3007.008	0.098	1626.136	-1.645	9.194	-0.265	1	-0.529	3	100	0	0	22.541	1	0	6	0	6	0	7	0	348.304
Pictilisib	0	1	0	0	0	4	0	0	513.631	5.79	799.979	408.541	155.6	215.882	19.956	1473.772	1	11.7	0.0227482	0.0146254	0.7829005	52.32	15.013	25.684	16.285	2.286	-4.527	-5.139	-6.801	82.651	-0.923	47.557	-5.305	8.534	1.188	4	0.046	3	61.687	0	0	109.332	10	1	30	0	30	8	35	0	0
Prednisolone	0	0	0	0	0	5	0	-2	360.449	1.378	578.899	303.406	194.391	81.101	0	1088.08	3	8.15	0.0017441	0.0243846	0.8837641	34.955	11.058	20.415	14.305	1.617	-3.22	-3.532	-3.8	142.065	-1.397	60.019	-4.336	10.414	0.859	4	-0.112	3	74.939	0	0	109.52	5	0	17	0	17	12	26	0	0.008
Prednisone	0	0	0	0	0	4	1	-2	358.433	3.375	573.045	291.41	200.837	80.798	0	1075.053	2	8.45	0.0105955	0.0208537	0.8856513	35.073	10.764	19.351	13.384	1.457	-3.466	-3.478	-3.768	123.414	-1.385	51.549	-4.552	10.348	0.745	5	-0.156	3	72.908	0	0	115.17	5	0	17	0	17	11	26	0	0.005
Pyrazole	9	0	0	0	0	0	0	1	68.078	3.097	227.793	0	71.455	156.338	0	308.706	1	1.5	0.0310629	0.0065849	0.9697392	7.693	3.074	4.514	4.759	0.26	-0.55	-0.457	-2.767	2081.091	0.057	1092.408	-2.286	9.736	-0.647	0	-0.786	3	87.859	0	0	30.86	2	0	5	0	5	0	5	0	348.51
Quinoline	4	0	0	0	0	0	0	1	129.161	2.136	329.535	0	21.956	307.579	0	505.888	0	1	0.0090178	0	0.9317512	17.029	5.387	5.677	3.739	2.091	-1.343	-1.951	-4.103	6133.295	0.395	3513.612	-0.841	9.004	0.898	1	-0.181	3	100	0	0	12.386	1	0	10	0	10	0	10	0	214.888
Resorcinol	6	0	0	0	0	2	0	-1	110.112	2.168	289.835	0	109.426	180.408	0	424.057	2	1.5	0.0110807	0.0073191	0.9418107	11.255	4.754	7.043	6.354	0.799	0.694	-1.136	-3.334	908.256	-0.38	445.839	-2.709	9.033	-0.213	2	-0.689	3	84.57	0	0	45.146	2	0	6	0	6	0	8	0	63.998
Rociletinib	2	0	0	0	1	7	1	-2	555.558	3.517	931.197	368.451	128.451	325.654	108.641	1661.745	3	10.25	0.0074455	0.0190653	0.7286179	58.964	17.448	30.063	20.563	4.372	-7.4	-6.821	-6.102	320.416	-1.205	1120.236	-2.068	8.013	0.577	3	0.354	1	84.432	108.641	34.181	114.823	10	1	24	0	24	4	40	1	0
Saracatinib	0	2	0	0	0	8	1	2	542.033	3.389	813.608	517.724	42.775	210.346	42.762	1550.205	1	11.2	0.0074083	0.0137658	0.7961768	52.757	14.952	24.864	14.146	3.324	-3.19	-4.804	-7.286	242.139	0.533	224.186	-4.924	8.348	0.95	6	0.195	3	76.122	0	0	77.894	10	1	31	0	31	10	38	0	0.004
Serine	7	1	0	1	0	4	0	-1	105.093	4.096	272.981	71.159	201.822	0	0	392.425	3	3.7	0.0427617	0.0234763	0.9495917	6.982	4.089	8.738	8.905	-3.314	0.309	0.581	-1.266	7.63	-0.771	3.58	-6.918	9.99	-1.096	4	-1.1	1	23.336	0	0	96.827	4	0	0	0	0	0	7	1	0.052
SNS-032	0	1	0	0	0	6	0	1	380.522	4.708	724.162	433.081	115.137	94.917	81.027	1245.55	2	7.5	0.0177948	0.0146467	0.7731021	40.747	12.41	20.474	11.912	2.915	-4.831	-3.534	-6.382	199.967	-0.485	267.002	-4.794	9.19	1.344	4	0.239	3	85.196	0	0	85.299	6	0	16	0	16	5	25	0	0
Sorafenib	1	0	0	0	1	5	0	-1	464.831	5.332	770.734	97.445	140.889	367.226	165.174	1316.177	3	6	0.021602	0.0134837	0.7535933	46.816	14.651	24.237	15.719	4.118	-7.09	-6.53	-5.896	320.652	-0.986	1704.17	-2.342	9.106	0.806	2	0.33	1	95.909	108.782	19.324	104.384	7	0	18	0	18	0	32	1	0
Sulbactam	0	0	0	1	1	1	1	-2	233.239	5.382	397.558	191.737	205.82	0	0	678.653	1	8	0.0426875	0.0201229	0.9394279	20.364	6.624	12.954	14.363	-1.115	0.406	-0.166	0.67	12.807	-1.052	13.211	-5.217	10.262	1.003	1	-1.389	2	40.238	0	42.747	118.843	6	0	7	4	3	5	15	1	3.603
Sunitinib	0	1	0	0	0	8	0	1	398.479	5.871	732.795	416.141	106.569	163.225	46.86	1311.168	2	6	0.0262843	0.0115793	0.7905964	42.741	12.526	20.409	10.409	3.946	-4.999	-4.654	-6.425	241.107	-0.542	212.407	-4.203	8.646	1.264	3	0.612	3	92.689	46.86	0	88.381	6	0	14	0	14	0	29	0	0
Tegafur	0	0	0	0	0	0	0	0	200.169	6.861	363.849	167.545	122.797	28.212	45.295	594.499	1	5.2	0.0791768	0.0142916	0.9397478	17.907	5.093	10.961	8.224	0.331	-1.614	-1.744	-2.641	678.291	-0.252	575.78	-3.683	9.722	0.718	1	-0.612	3	79.562	45.295	0	82.597	5	0	11	0	11	4	14	0	1.01
Temozolomide	1	0	0	0	0	1	0	-2	194.152	3.411	379.129	87.887	235.051	56.19	0	597.216	2	7	0.0194771	0.0261112	0.9046201	17.641	6.286	12.749	12.216	-1.22	-1.381	-1.328	-3.343	58.466	-1.412	22.989	-5.558	9.649	1.801	1	-0.8	2	51.425	0	0	130.572	8	0	9	0	9	0	14	0	0.022
Tivozanib	0	0	0	0	1	6	0	-2	454.869	8.739	764.785	281.97	128.884	288.133	65.798	1335.424	2	6.5	0.0571878	0.0120196	0.7668411	46.189	14.668	22.678	14.095	3.846	-6.269	-6.42	-5.304	392.951	-1.098	645.931	-2.304	8.785	1.059	4	0.331	1	95.899	0	22.533	107.156	9	0	21	0	21	0	32	1	0.001
Tocotrienol	6	0	0	0	0	10	0	0	382.585	3.281	779.704	581.006	54.683	144.015	0	1426.355	1	1.5	0.007545	0.0019238	0.7859353	45.883	13.2	16.797	3.683	7.446	-8.37	-6.797	-5.683	3001.534	-0.629	1622.936	-1.06	8.649	-0.221	11	1.831	1	100	0	0	29.163	2	1	10	0	10	3	28	2	0
Trametinib	1	0	0	0	0	3	0	-1	615.402	6.883	791.25	328.953	134.251	206.143	121.903	1484.145	1	8.5	0.0319238	0.0107425	0.7952469	53.284	15.001	24.903	13.157	4.792	-7.476	-9.457	-5.828	528.199	-0.733	1154.814	-2.98	8.623	1.097	1	0.807	1	90.779	39.694	0	123.888	9	1	25	3	22	3	37	1	0
Tyrosine	0	1	0	1	0	5	0	-1	181.191	3.643	392.324	48.949	197.573	145.802	0	627.352	4	3.75	0.0211499	0.0191168	0.9033592	17.135	7.418	13.573	11.448	-1.872	-0.624	-0.684	-2.71	8.372	-0.953	3.958	-6.23	8.873	-0.359	5	-0.847	2	32.502	0	0	96.476	4	0	6	0	6	0	13	1	0.025
Vandetanib	0	1	0	0	0	6	0	1	475.36	6.068	767.33	367.17	42.52	248.583	109.056	1347.126	1	6	0.0273345	0.0078193	0.7687559	46.279	13.532	20.311	9.635	5.095	-6.276	-6.435	-7.185	976.293	0.388	2110.446	-2.914	8.478	1.106	4	0.823	1	100	31.677	0	52.352	6	1	22	0	22	5	30	1	0
Vemurafenib	0	0	0	0	0	7	0	-1	489.923	6.199	690.891	142.936	147.089	269.331	131.535	1307.083	1	6.5	0.0293981	0.0094081	0.8368051	44.233	13.593	20.817	10.583	4.574	-5.879	-7.841	-5.457	399.074	-0.936	963.133	-2.61	8.866	1.2	1	0.6	3	100	61.622	0	98.977	6	0	21	0	21	0	33	1	0.002
Vinblastine	7	3	0	0	0	8	1	1	810.986	6.812	1060.966	741.924	109.797	209.246	0	2270.617	2	12.25	0.0204372	0.0163286	0.7874554	81.578	21.451	37.6	17.673	6.172	-5.777	-8.453	-8.148	13.976	-0.302	6.628	-6.163	7.919	0.039	7	1.932	1	44.706	0	0	139.412	13	3	38	0	34	18	59	3	0
Vincristine	6	2	0	0	0	8	1	-2	824.969	6.485	1046.149	646.754	197.772	201.624	0	2246.809	2	14.25	0.0187184	0.0192635	0.7930164	80.552	21.753	38.743	20.154	5.082	-5.961	-8.946	-7.295	8.208	-1.218	3.37	-7.811	8.062	0.46	5	1.455	2	34.187	0	0	177.064	14	3	38	0	34	18	60	2	0
Vinorelbine	8	3	0	0	0	7	1	1	778.944	6.81	1044.046	734.996	88.611	220.438	0	2195.202	1	11.5	0.0211251	0.0110148	0.7823995	79.308	20.622	34.823	15.582	6.269	-5.882	-8.359	-8.283	22.197	-0.026	10.928	-5.829	7.769	-0.003	9	1.91	1	48.871	0	0	116.806	12	3	37	0	34	15	57	3	0
Zosuquidar	2	2	0	0	0	6	2	2	527.613	3.07	857.881	204.652	60.924	521.481	70.824	1593.22	1	7.45	0.0059162	0.0086842	0.768992	58.734	17.092	25.586	13.249	5.552	-5.933	-6.026	-9.209	162.915	0.486	208.118	-4.354	8.622	0.771	9	1.187	2	73.125	70.824	0	47.986	5	2	32	3	28	8	39	2	0

Clinical Trials of the Found Drugs/Small Molecules

Clinical Trials from clinicaltrials.gov (06-17-2024)

Fusion Gene Other terms in clinicaltrials.gov	Samll molecule Intervention in clinicaltrials.gov	NCT ID	Study Status	Phases	Disease	# Enrolment	Date
EML4-ALK	Brigatinib	NCT04223596	Active, not recruiting	Phase 2	Lung Cancer	33	April 15, 2025
EML4-ALK	Crizotinib	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	Lorlatinib	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	Tyrosine	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	AUY922	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Carboplatin	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Ceritinib	NCT02292550	Completed	Phase 1	Non-small Cell Lung Cancer	27	September 26, 2018
EML4-ALK	Cisplatin	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Crizotinib	NCT00932451	Completed	Phase 2	Carcinoma, Non-Small-Cell Lung	1069	December 2015
EML4-ALK	Crizotinib	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Crizotinib	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Crizotinib	NCT01300429	Completed		Lung Cancer	30	January 5, 2021
EML4-ALK	D-glucose	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Erlotinib	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Pemetrexed	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Tyrosine	NCT00932451	Completed	Phase 2	Carcinoma, Non-Small-Cell Lung	1069	December 2015
EML4-ALK	Tyrosine	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Tyrosine	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Tyrosine	NCT01300429	Completed		Lung Cancer	30	January 5, 2021
EML4-ALK	Tyrosine	NCT02292550	Completed	Phase 1	Non-small Cell Lung Cancer	27	September 26, 2018
EML4-ALK	Crizotinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Erlotinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Gefitinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Osimertinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Afatinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Erlotinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Gefitinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Tyrosine	NCT01574300	Terminated		Non-small Cell Lung Cancer Metastatic	136	March 1, 2019
EML4-ALK	Erlotinib	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Gefitinib	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Gemcitabine	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Platinum	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Brigatinib	NCT04223596	Active, not recruiting	Phase 2	Lung Cancer	33	April 15, 2025
EML4-ALK	Crizotinib	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	Lorlatinib	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	Tyrosine	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	AUY922	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Carboplatin	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Ceritinib	NCT02292550	Completed	Phase 1	Non-small Cell Lung Cancer	27	September 26, 2018
EML4-ALK	Cisplatin	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Crizotinib	NCT00932451	Completed	Phase 2	Carcinoma, Non-Small-Cell Lung	1069	December 2015
EML4-ALK	Crizotinib	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Crizotinib	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Crizotinib	NCT01300429	Completed		Lung Cancer	30	January 5, 2021
EML4-ALK	D-glucose	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Erlotinib	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Pemetrexed	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Tyrosine	NCT00932451	Completed	Phase 2	Carcinoma, Non-Small-Cell Lung	1069	December 2015
EML4-ALK	Tyrosine	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Tyrosine	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Tyrosine	NCT01300429	Completed		Lung Cancer	30	January 5, 2021
EML4-ALK	Tyrosine	NCT02292550	Completed	Phase 1	Non-small Cell Lung Cancer	27	September 26, 2018
EML4-ALK	Crizotinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Erlotinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Gefitinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Osimertinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Afatinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Erlotinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Gefitinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Tyrosine	NCT01574300	Terminated		Non-small Cell Lung Cancer Metastatic	136	March 1, 2019
EML4-ALK	Erlotinib	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Gefitinib	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Gemcitabine	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Platinum	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Brigatinib	NCT04223596	Active, not recruiting	Phase 2	Lung Cancer	33	April 15, 2025
EML4-ALK	Crizotinib	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	Lorlatinib	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	Tyrosine	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	AUY922	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Carboplatin	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Ceritinib	NCT02292550	Completed	Phase 1	Non-small Cell Lung Cancer	27	September 26, 2018
EML4-ALK	Cisplatin	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Crizotinib	NCT00932451	Completed	Phase 2	Carcinoma, Non-Small-Cell Lung	1069	December 2015
EML4-ALK	Crizotinib	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Crizotinib	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Crizotinib	NCT01300429	Completed		Lung Cancer	30	January 5, 2021
EML4-ALK	D-glucose	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Erlotinib	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Pemetrexed	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Tyrosine	NCT00932451	Completed	Phase 2	Carcinoma, Non-Small-Cell Lung	1069	December 2015
EML4-ALK	Tyrosine	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Tyrosine	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Tyrosine	NCT01300429	Completed		Lung Cancer	30	January 5, 2021
EML4-ALK	Tyrosine	NCT02292550	Completed	Phase 1	Non-small Cell Lung Cancer	27	September 26, 2018
EML4-ALK	Crizotinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Erlotinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Gefitinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Osimertinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Afatinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Erlotinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Gefitinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Tyrosine	NCT01574300	Terminated		Non-small Cell Lung Cancer Metastatic	136	March 1, 2019
EML4-ALK	Erlotinib	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Gefitinib	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Gemcitabine	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Platinum	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Brigatinib	NCT04223596	Active, not recruiting	Phase 2	Lung Cancer	33	April 15, 2025
EML4-ALK	Crizotinib	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	Lorlatinib	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	Tyrosine	NCT03052608	Active, not recruiting	Phase 3	Carcinoma, Non-Small-Cell Lung	296	December 31, 2028
EML4-ALK	AUY922	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Carboplatin	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Ceritinib	NCT02292550	Completed	Phase 1	Non-small Cell Lung Cancer	27	September 26, 2018
EML4-ALK	Cisplatin	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Crizotinib	NCT00932451	Completed	Phase 2	Carcinoma, Non-Small-Cell Lung	1069	December 2015
EML4-ALK	Crizotinib	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Crizotinib	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Crizotinib	NCT01300429	Completed		Lung Cancer	30	January 5, 2021
EML4-ALK	D-glucose	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Erlotinib	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Pemetrexed	NCT01154140	Completed	Phase 3	Non Squamous Lung Cancer	343	November 30, 2016
EML4-ALK	Tyrosine	NCT00932451	Completed	Phase 2	Carcinoma, Non-Small-Cell Lung	1069	December 2015
EML4-ALK	Tyrosine	NCT00965731	Completed	Phase 1	Non-Small Cell Lung Cancer	27	January 2014
EML4-ALK	Tyrosine	NCT01124864	Completed	Phase 2	Non-small-cell Lung Cancer	153	August 2014
EML4-ALK	Tyrosine	NCT01300429	Completed		Lung Cancer	30	January 5, 2021
EML4-ALK	Tyrosine	NCT02292550	Completed	Phase 1	Non-small Cell Lung Cancer	27	September 26, 2018
EML4-ALK	Crizotinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Erlotinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Gefitinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Osimertinib	NCT01994057	Recruiting		Non-small Cell Lung Cancer (NSCLC)	1000	December 2026
EML4-ALK	Afatinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Erlotinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Gefitinib	NCT02762877	Terminated		Non Small Cell Lung Carcinoma	140	June 19, 2019
EML4-ALK	Tyrosine	NCT01574300	Terminated		Non-small Cell Lung Cancer Metastatic	136	March 1, 2019
EML4-ALK	Erlotinib	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Gefitinib	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Gemcitabine	NCT01100840	Unknown status		Non Small Cell Lung Cancer
EML4-ALK	Platinum	NCT01100840	Unknown status		Non Small Cell Lung Cancer

Fusion-Positive Patients' Treatment Records

Fusion-Positive Patients' Treatment Records in TCGA cohorts

Fusion Gene	Drugs
EML4-ALK	ALIMTA, Alimta, CISPLATIN, Cisplatin

Generative AI Summary Sentence of the Relationship Between Fusion Gene and Small Molecule that Have at Least Thrree PMIDs from PubMed

Generative AI summary sentence of the relationship between fusion gene and small molecule that have at least thrree PMIDs from PubMed using the ChatGPT 4

Found PMIDs	Fusion Gene	Drugs	Once Sentence Summary
# pmid >4	EML4-ALK	Afatinib	EML4-ALK and Afatinib: Afatinib is an EGFR and HER2 inhibitor, used primarily for treating NSCLC with EGFR mutations rather than EML4-ALK-positive NSCLC.
# pmid >4	EML4-ALK	Alectinib	EML4-ALK and Alectinib: Alectinib is a targeted therapy used to treat non-small cell lung cancer (NSCLC) in patients with the EML4-ALK fusion gene, providing effective inhibition of ALK activity and showing significant clinical benefits.
# pmid >4	EML4-ALK	Aniline	EML4-ALK and Aniline: There is no direct relationship between EML4-ALK and aniline in the context of cancer treatment, as aniline is a chemical compound used in the manufacturing of dyes, drugs, and plastics.
# pmid >1	EML4-ALK	Anlotinib	EML4-ALK and Anlotinib: Anlotinib shows potential in inhibiting the growth of EML4-ALK positive lung cancer cells.
# pmid >1	EML4-ALK	ATP	EML4-ALK and ATP: EML4-ALK fusion protein activity is dependent on ATP binding.
# pmid >1	EML4-ALK	AUY922	EML4-ALK and AUY922: AUY922 effectively inhibits the growth of EML4-ALK positive cancer cells.
# pmid >4	EML4-ALK	Brigatinib	EML4-ALK and Brigatinib: Brigatinib is an ALK inhibitor used for the treatment of NSCLC in patients with the EML4-ALK fusion gene, offering another option for patients who have developed resistance to other ALK inhibitors.
# pmid >1	EML4-ALK	Capmatinib	EML4-ALK and Capmatinib: Capmatinib is effective in treating EML4-ALK positive non-small cell lung cancer.
# pmid >4	EML4-ALK	Carboplatin	EML4-ALK and Carboplatin: Carboplatin is a chemotherapy drug used to treat various cancers, including NSCLC, and can be used in combination with targeted therapies in patients with EML4-ALK fusion genes.
# pmid >4	EML4-ALK	Ceritinib	EML4-ALK and Ceritinib: Ceritinib is another ALK inhibitor used for the treatment of NSCLC in patients with the EML4-ALK fusion gene, especially in cases where the disease has progressed despite prior treatment with other ALK inhibitors.
# pmid >1	EML4-ALK	Cisplatin	EML4-ALK and Cisplatin: Cisplatin is used in combination therapies to treat cancers with the EML4-ALK fusion gene.
# pmid >4	EML4-ALK	Crizotinib	EML4-ALK and Crizotinib: Crizotinib targets the ALK kinase activity in cancers harboring the EML4-ALK fusion, leading to significant clinical responses and improvement in progression-free survival for patients with ALK-positive non-small cell lung cancer .
# pmid >2	EML4-ALK	Dabrafenib	EML4-ALK and Dabrafenib: Dabrafenib is not typically used for EML4-ALK fusion-positive cancers, as it primarily targets BRAF-mutated cancers.
# pmid >4	EML4-ALK	Docetaxel	EML4-ALK and Docetaxel: Docetaxel is a chemotherapy drug used to treat NSCLC, including cases with EML4-ALK fusion genes, particularly in second-line settings after the failure of targeted therapies.
# pmid >4	EML4-ALK	Ensartinib	EML4-ALK and Ensartinib: Ensartinib is a next-generation ALK inhibitor used to treat non-small cell lung cancer (NSCLC) patients with EML4-ALK fusion genes, showing efficacy in cases resistant to other ALK inhibitors.
# pmid >4	EML4-ALK	Entrectinib	EML4-ALK and Entrectinib: Entrectinib is a multi-targeted kinase inhibitor that targets ALK, ROS1, and NTRK, and is used to treat NSCLC patients with EML4-ALK fusion genes, showing effectiveness in those with central nervous system metastases.
# pmid >1	EML4-ALK	Eosin	EML4-ALK and Eosin: EML4-ALK fusion gene is linked to eosin-positive cancers.
# pmid >4	EML4-ALK	Erlotinib	EML4-ALK and Erlotinib: Erlotinib is primarily an EGFR inhibitor and is not specifically used for treating EML4-ALK-positive NSCLC; it is more effective in patients with EGFR mutations.
# pmid >2	EML4-ALK	Etoposide	EML4-ALK and Etoposide: Etoposide has been used in combination regimens for EML4-ALK-positive lung cancers, although it is not a targeted therapy.
# pmid >2	EML4-ALK	Ganetespib	EML4-ALK and Ganetespib: Ganetespib, an HSP90 inhibitor, has shown preclinical activity against EML4-ALK fusion-positive lung cancers.
# pmid >4	EML4-ALK	Gefitinib	EML4-ALK and Gefitinib: Similar to Erlotinib, Gefitinib is an EGFR inhibitor and is not specifically indicated for EML4-ALK-positive NSCLC, targeting instead EGFR mutations.
# pmid >1	EML4-ALK	Geldanamycin	EML4-ALK and Geldanamycin: Geldanamycin inhibits the Hsp90 chaperone protein, leading to the degradation of the EML4-ALK fusion protein and exhibiting anti-cancer effects.
# pmid >4	EML4-ALK	Gemcitabine	EML4-ALK and Gemcitabine: Gemcitabine is a chemotherapy drug that can be used to treat NSCLC, including cases with EML4-ALK fusion genes, often in combination with other chemotherapy agents or targeted therapies.
# pmid >1	EML4-ALK	Gilteritinib	EML4-ALK and Gilteritinib: Gilteritinib is effective in targeting EML4-ALK fusion-positive cancers by inhibiting the ALK kinase activity.
# pmid >1	EML4-ALK	Icotinib	EML4-ALK and Icotinib: Icotinib has shown activity against tumors with the EML4-ALK fusion, being a potential treatment option for patients with this genetic alteration.
# pmid >1	EML4-ALK	Imatinib	EML4-ALK and Imatinib: Imatinib has limited efficacy against EML4-ALK fusion proteins found in non-small cell lung cancer, as these require targeted ALK inhibitors for effective treatment .
# pmid >4	EML4-ALK	Lorlatinib	EML4-ALK and Lorlatinib: Lorlatinib is an ALK inhibitor designed to treat patients with NSCLC who have the EML4-ALK fusion gene, particularly those who have developed resistance to first and second-generation ALK inhibitors.
# pmid >1	EML4-ALK	Nedaplatin	EML4-ALK and Nedaplatin: Nedaplatin shows effectiveness in EML4-ALK positive lung cancer.
# pmid >4	EML4-ALK	Osimertinib	EML4-ALK and Osimertinib: Osimertinib is primarily an EGFR inhibitor and is used to treat NSCLC with specific EGFR mutations, not typically used for EML4-ALK-positive cancers.
# pmid >2	EML4-ALK	Paclitaxel	EML4-ALK and Paclitaxel: Paclitaxel is used in combination with other therapies in treating EML4-ALK-positive non-small cell lung cancer, enhancing the overall efficacy.
# pmid >4	EML4-ALK	Pemetrexed	EML4-ALK and Pemetrexed: Pemetrexed is a chemotherapy drug that can be used to treat NSCLC, including cases with the EML4-ALK fusion gene, but it is not a targeted therapy and works by inhibiting cell division.
# pmid >4	EML4-ALK	Platinum	EML4-ALK and Platinum: Platinum-based chemotherapy agents, such as cisplatin and carboplatin, are used in the treatment of NSCLC and can be part of combination therapies for patients with EML4-ALK fusion genes.
# pmid >1	EML4-ALK	Saracatinib	EML4-ALK and Saracatinib: Saracatinib has been shown to inhibit EML4-ALK activity in preclinical studies.
# pmid >2	EML4-ALK	Serine	EML4-ALK and Serine: The interaction between EML4-ALK and serine is not well-documented in scientific literature.
# pmid >2	EML4-ALK	Sirolimus	EML4-ALK and Sirolimus: Sirolimus, an mTOR inhibitor, has shown potential in treating EML4-ALK-positive cancers by inhibiting downstream signaling pathways.
# pmid >2	EML4-ALK	Sorafenib	EML4-ALK and Sorafenib: Sorafenib, a multikinase inhibitor, has limited efficacy in EML4-ALK-positive cancers compared to other targeted therapies.
# pmid >1	EML4-ALK	Sotorasib	EML4-ALK and Sotorasib: Sotorasib shows efficacy in EML4-ALK positive cells by inhibiting KRAS G12C mutations, reducing cell proliferation.
# pmid >2	EML4-ALK	Trametinib	EML4-ALK and Trametinib: Trametinib, a MEK inhibitor, is not typically used for EML4-ALK fusion-positive cancers, as it primarily targets the MAPK pathway.
# pmid >4	EML4-ALK	Tyrosine	EML4-ALK and Tyrosine: Tyrosine is an amino acid and not directly related to the treatment of EML4-ALK-positive NSCLC; however, tyrosine kinase inhibitors (TKIs) are a class of drugs that target various tyrosine kinases, including ALK.
# pmid >2	EML4-ALK	Vandetanib	EML4-ALK and Vandetanib: Vandetanib, targeting multiple tyrosine kinases, has shown limited efficacy in EML4-ALK-positive cancers.
# pmid >2	EML4-ALK	Vemurafenib	EML4-ALK and Vemurafenib: Vemurafenib, primarily targeting BRAF mutations, is not effective for EML4-ALK fusion-positive cancers.
# pmid >1	EML4-ALK	Vinorelbine	EML4-ALK and Vinorelbine: Vinorelbine has shown efficacy in treating patients with EML4-ALK positive non-small cell lung cancer .
check	EML4-ALK	X-396	EML4-ALK and X-396: EML4-ALK fusion is a therapeutic target for X-396, a potent ALK inhibitor, in non-small cell lung cancer.